

CITATION REPORT

List of articles citing

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

DOI: 10.2337/diacare.28.5.1092
Diabetes Care, 2005, 28, 1092-100.

Source: <https://exaly.com/paper-pdf/38807009/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1310	Drugs used in diabetes mellitus. 83-92		
1309	Current and investigational antiobesity agents and obesity therapeutic treatment targets. 2004 , 12, 1197-211		164
1308	Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. <i>Diabetes Care</i> , 2004 , 27, 2628-35	14.6	1088
1307	Proglucagon-derived peptides: mechanisms of action and therapeutic potential. 2005 , 20, 357-65		61
1306	New sources of pancreatic beta-cells. 2005 , 23, 857-61		346
1305	Exenatide. 2005 , 4, 713-4		76
1304	Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches. 2005 , 5, 346-52		6
1303	Drugs on the horizon for diabetes. 2005 , 5, 353-9		43
1302	Glucagon-like peptide 1 (GLP-1) and incretin mimetics for the treatment of diabetes. 2005 , 22, 171-179		4
1301	Exenatide Injection. 2005 , 40, 994-1003		
1300	GLP-1, Incretin Mimetics and DPP 4 Inhibitors: New Ways in the Treatment of Type 2 Diabetes. 2005 , 5, 485-497		2
1299	The incretin mimetic, exenatide: a novel treatment option for type 2 diabetes. 2005 , 5, 227-235		3
1298	Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. <i>Diabetes Care</i> , 2005 , 28, 1083-91	14.6	1034
1297	Biologic actions and therapeutic potential of the proglucagon-derived peptides. 2005 , 1, 22-31		171
1296	Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. 2005 , 7, 467-77		77
1295	Does exenatide provide a meaningful new treatment option for patients with type 2 diabetes?. 2005 , 1, 70-1		
1294	Investigational agents that protect pancreatic islet beta-cells from failure. 2005 , 14, 1241-50		6

1293	Medications associated with weight gain. 2005 , 39, 2046-55		53
1292	Emerging role of protein kinase B/Akt signaling in pancreatic beta-cell mass and function. 2006 , 38, 157-63		34
1291	Exenatide. 2005 , 65, 1681-92; discussion 1693-5		51
1290	Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. 2005 , 90, 5991-7		255
1289	Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. 2005 , 4, 361-70		55
1288	Oxyntomodulin : a novel potential treatment for obesity. 2006 , 5, 265-72		20
1287	Update in the pharmacologic treatment of diabetes mellitus: focus on pramlintide and exenatide. 2006 , 32, 693-712		13
1286	Therapeutic approaches to preserve islet mass in type 2 diabetes. 2006 , 57, 265-81		124
1285	Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , 2006 , 29, 1963-72	14.6	935
1284	Recent evidence of sustained benefit with exenatide in Type 2 diabetes. 2006 , 7, 2003-6		5
1283	Glycemic control in the metabolic syndrome and implications in preventing cardiovascular disease. 2006 , 4, 315-27		3
1282	Is exenatide advancing the treatment of type 2 diabetes?. 2006 , 7, 109-12		2
1281	Pharmacotherapies for diabetes management: an update for the practicing clinician. 2006 , 18, 379-89		3
1280	Tight control of hyperglycemia in type 2 diabetes mellitus. 2006 , 1, 166-172		8
1279	GLP-1: a new approach for type 2 diabetes therapy. 2006 , 74, S152-S155		19
1278	Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. 2006 , 368, 1660-72		624
1277	The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. 2006 , 368, 1696-705		2861
1276	[New approaches in obesity treatment: the gastrointestinal tract as an endocrine organ]. 2006 , 127, 300-5		1

1275	Diabetes: assessing the pipeline. 2006 , 7, 43-9	11
1274	Incretin-based therapies for type 2 diabetes: clinical utility. 2006 , 35 Suppl 1, 12-6; discussion 17-19	2
1273	The application of evidence-based principles of care in older persons (issue 3): management of diabetes mellitus. 2006 , 7, 234-40	29
1272	Hiperglucemia posprandial: importancia y tratamiento. 2006 , 53, 137-142	
1271	Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. 2006 , 4, 80	58
1270	Intravail: highly effective intranasal delivery of peptide and protein drugs. 2006 , 3, 529-39	44
1269	Targeting postprandial hyperglycemia. 2006 , 55, 1263-81	62
1268	Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. 2006 , 281, 1159-68	167
1267	Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. 2006 , 28, 55-72	237
1266	Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. 2006 , 28, 652-65	70
1265	The biology of incretin hormones. 2006 , 3, 153-65	1583
1264	Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein. 2006 , 346, 1067-74	82
1263	Emerging role of protein kinase B/Akt signaling in pancreatic β cell mass and function. 2006 , 38, 689-695	47
1262	Immunogenicity of xenopeptide hormone therapies. 2006 , 27, 1902-10	20
1261	Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience. 2006 , 12, 726-35	26
1260	Is exenatide a useful addition to diabetes therapy?. 2006 , 12, 307-14	4
1259	Therapeutic options in development for management of diabetes: pharmacologic agents and new technologies. 2006 , 12 Suppl 1, 142-7	12
1258	What are incretins, and how will they influence the management of type 2 diabetes?. 2006 , 12, S2-12; quiz S14-6	4

1257	Exenatide: a novel approach for treatment of type 2 diabetes. 2006 , 99, 1271-9	12
1256	Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus. 2006 , 19, 281-4	55
1255	Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea. 2006 , 2006, 1-4	
1254	Do Age and Comorbidity Affect Intensity of Pharmacological Therapy for Poorly Controlled Diabetes Mellitus?. 2006 , 2006, 4-6	
1253	Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. 2006 , 46, 1179-87	42
1252	Obesity and type 2 diabetes mellitus in adolescents: what is new?. 2006 , 13, 111-118	
1251	Exenatide: a novel incretin mimetic agent for treating type 2 diabetes mellitus. 2006 , 14, 205-11	20
1250	Obesity: new perspectives and pharmacotherapies. 2006 , 14, 238-58	30
1249	Current World Literature. 2006 , 13, 460-462	
1248	Oxyntomodulin. 2006 , 13, 49-55	4
1247	Current World Literature. 2006 , 13, 76-98	
1246	Current World Literature. 2006 , 13, 377-401	
1245	Regulation of food intake by gastrointestinal hormones. 2006 , 22, 626-31	37
1244	Exenatide: from the Gila monster to the pharmacy. 2006 , 46, 44-52; quiz 53-5	31
1243	Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. 2006 , 8, 419-28	180
1242	Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. 2006 , 8, 436-47	360
1241	Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes. 2006 , 23, 240-5	39
1240	Therapeutic intervention in the GLP-1 pathway in Type 2 diabetes. 2006 , 23 Suppl 1, 14-9	5

1239	Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data. 2006 , 60, 1654-61	40
1238	Managing older adults with diabetes. 2006 , 18, 309-17	12
1237	The obesity pipeline: current strategies in the development of anti-obesity drugs. 2006 , 5, 919-31	164
1236	Gut hormones and the regulation of energy homeostasis. 2006 , 444, 854-9	560
1235	[Pharmacotherapy of obesity]. 2006 , 35, 500-4	
1234	Current and novel approaches to the drug therapy of obesity. 2006 , 62, 793-803	19
1233	Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. 2006 , 49, 253-60	171
1232	Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. 2006 , 49, 452-8	221
1231	Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. 2006 , 49, 1711-21	303
1230	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. 2006 , 49, 2564-71	504
1229	Medikamentöse Therapie der Adipositas. 2006 , 2, 233-242	
1228	Metabolisches Syndrom und kardiovaskuläre Komplikationen. 2006 , 1, 55-67	
1227	What to inject when oral agents fail?. 2006 , 6, 341-3	
1226	How do different GLP-1 mimetics differ in their actions?. 2006 , 6, 365-72	4
1225	Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus. 2006 , 26, 360-74	27
1224	New and emerging strategies for reducing cardiometabolic risk factors. 2006 , 26, 13S-31S; quiz 43S-45S	9
1223	Evaluating and treating cardiometabolic risk factors: a case discussion. 2006 , 26, 32S-41S	
1222	Exenatide effects on glucose metabolism and metabolic disorders common to overweight and obese patients with type 2 diabetes. 2006 , 67, 666-676	3

1221	Management of type 2 diabetes: the role of incretin mimetics. 2006 , 67, 545-552	1
1220	Therapeutic applications of incretin mimetics for metabolic diseases: preclinical studies. 2006 , 67, 553-558	3
1219	Current literature in diabetes. 2006 , 22, i-xii	
1218	Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. 2006 , 22, 483-91	89
1217	Management of Type 2 diabetes: the role of incretin mimetics. 2006 , 7, 2095-105	24
1216	Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. 2006 , 114, 417-23	120
1215	Strukturierte Adipositas therapie. 2006 , 21, 163-172	
1214	Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. 2006 , 38, 838-44	62
1213	Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus. 2006 , 7, 1055-64	48
1212	Preventive Cardiology. 2006 ,	
1211	Challenges and strategies for moving patients to injectable medications. 2006 , 32 Suppl 2, 825-90S	10
1210	Role of phosphatidylinositol 3-kinase gamma in the beta-cell: interactions with glucagon-like peptide-1. 2006 , 147, 3318-25	29
1209	Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. 2006 , 30, 1332-40	107
1208	Anticipating disaster: the genetics of familial pancreatic cancer. 2006 , 55, 150-1	3
1207	The evidence for achieving glycemic control with incretin mimetics. 2006 , 32 Suppl 2, 72S-81S	2
1206	Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. <i>Diabetes Care</i> , 2006 , 29, 435-49	14.6 87
1205	To be or not to be--an incretin or enterogastrone?. 2006 , 55, 148-50	23
1204	Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice. 2006 , 318, 914-21	45

1203	Exenatide: a new option for the treatment of type 2 diabetes. 2006 , 40, 1777-84		24
1202	Clinical observations of exenatide treatment. <i>Diabetes Care</i> , 2006 , 29, 1984	14.6	25
1201	Exenatide. 2006 , 63, 411-8		26
1200	Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes. 2006 , 8, 385-96		39
1199	Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. 2006 , 55, 3387-93		143
1198	Lymphocytic infiltration and immune activation in metallothionein promoter-exendin-4 (MT-Exendin) transgenic mice. 2006 , 55, 1562-70		17
1197	Gut peptides in the regulation of food intake and energy homeostasis. 2006 , 27, 719-27		179
1196	Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus. 2006 , 1, 329-341		18
1195	Clinical Investigations of Antiobesity Drugs. 2007 , 337-III		3
1194	Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. <i>Diabetes Care</i> , 2007 , 30, 2767-72	14.6	86
1193	Missing the point: substituting exenatide for nonoptimized insulin: going from bad to worse!. <i>Diabetes Care</i> , 2007 , 30, 2972-3	14.6	21
1192	Novel Approaches to Diabetes Treatment. 2007 , 140, 28-29		
1191	Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. <i>Diabetes Care</i> , 2007 , 30, 890-5	14.6	365
1190	DPP-4 inhibitors as a new target of action for Type 2 diabetes mellitus: a focus on vildagliptin. 2007 , 2, 567-572		
1189	Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats. 2007 , 293, G288-95		28
1188	The physiology of incretin hormones and the basis for DPP-4 inhibitors. 2007 , 33, 55-6, 60-2, 65-6		18
1187	Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus. 2007 , 41, 51-60		35
1186	Adapting the GLP-1-signaling system to the treatment of type 2 diabetes. 2007 , 3, 15-23		6

1185	New Horizons in Diabetes Therapy. 2007 , 7, 49-55	3
1184	GLP-1 as a Therapeutic Agent in Patients with Type 2 Diabetes Mellitus. 2007 , 1, 193-201	
1183	Diabetic gastroparesis. 2007 , 357, 418; author reply 419-20	2
1182	Emerging Therapies for Type 2 Diabetes. 2007 , 2, 151-160	7
1181	Indikationsgebiete inkretinbasierter Therapien: Analyse von Studienpopulation, Studiendesign und Effektivität in Exenatide- und DDP-4-Inhibitor-Studien. 2007 , 2, 315-320	
1180	beta-cell failure in diabetes and preservation by clinical treatment. 2007 , 28, 187-218	556
1179	[Recent examples for drug (developments) in primary, secondary and tertiary prevention]. 2007 , 132, 2212-6	
1178	Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. 2007 , 23, 609-22	49
1177	Safety and adverse effects associated with GLP-1 analogues. 2007 , 6, 417-22	6
1176	Pharmacological treatment of the overweight patient. 2007 , 59, 151-84	131
1175	Geriatric Diabetes. 2007 ,	2
1174	Expanded Use of Exenatide in the Management of Type 2 Diabetes. 2007 , 20, 59-63	20
1173	Case study 2: new insights: clinical pearls for using incretin mimetics in type 2 diabetes. 2007 , 33 Suppl 1, 14S-19S	2
1172	Emerging Treatments for Patients With Type 2 Diabetes. 2007 , 33, 105S-110S	
1171	American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. 2007 , 13 Suppl 1, 1-68	446
1170	The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. 2007 , 28, 253-83	285
1169	Exploring treatment strategies for type 2 diabetes. <i>Diabetes Care</i> , 2007 , 30, 2737-45	14.6 17
1168	Allosteric modulators of class B G-protein-coupled receptors. 2007 , 5, 168-79	36

1167	Diabetes beyond insulin: review of new drugs for treatment of diabetes mellitus. 2007 , 4, 39-47	50
1166	Metformin Π life begins at 50: A symposium held on the occasion of the 43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam, The Netherlands, September 2007. 2007 , 7, 247-252	5
1165	Nonpeptidic glucagon-like peptide 1 receptor agonists: a magic bullet for diabetes?. 2007 , 104, 689-90	25
1164	Dipeptidyl peptidase-IV inhibitors: fixing type 2 diabetes?. 2007 , 68, 599-602	2
1163	Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. 2007 , CD005166	50
1162	Newly approved and promising antidiabetic agents. 2007 , 62, 293-310	19
1161	Stem cells for the treatment of diabetes. 2007 , 54, 7-16	39
1160	New drugs for the treatment of type 2 diabetes. 2007 , 68, 178-83	3
1159	Peptide binding at the GLP-1 receptor. 2007 , 35, 713-6	32
1158	The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. 2007 , 146, 477-85	343
1157	Glucagon-like peptide analogues for type 2 diabetes mellitus. 2007 ,	7
1156	Incretins and their role in the management of diabetes. 2007 , 14, 269-76	21
1155	Combination therapy with new targets in Type 2 diabetes: a review of available agents with a focus on pre-exercise adjustment. 2007 , 27, 193-201	10
1154	Basal-prandial insulin: when is the right time to initiate treatment?. 2007 , 32, 24-9; quiz 29-30	
1153	Bibliography. Current world literature. Diabetes and the endocrine pancreas. 2007 , 14, 170-96	
1152	Using propensity scores subclassification to estimate effects of longitudinal treatments: an example using a new diabetes medication. 2007 , 45, S149-57	8
1151	Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. 2007 , 83, 24-8	110
1150	A 74-year-old woman with diabetes. 2007 , 297, 196-204	12

1149	Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. 2007 , 14, 98-107	56
1148	Standards of care and the burden of treatment failure in type 2 diabetes. 2007 , Suppl Initiating Insulin, 3-8	
1147	Insulin treatment in managing type 2 diabetes: challenges and opportunities. 2007 , Suppl Initiating Insulin, 9-21	
1146	Clinical management strategies for type 2 diabetes. 2007 , Suppl, 9-14	2
1145	Biological activity of AC3174, a peptide analog of exendin-4. 2007 , 141, 113-9	32
1144	Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion. 2007 , 143, 64-8	61
1143	Incretin-based therapies: mimetics versus protease inhibitors. 2007 , 18, 240-5	41
1142	Therapeutic options for modifying cardiometabolic risk factors. 2007 , 120, S26-34	23
1141	Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. 2007 , 29, 139-53	235
1140	Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy. 2007 , 29, 1784-94	13
1139	Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. 2007 , 29, 2333-48	218
1138	Medical therapy for obesity--current status and future hopes. 2007 , 91, 1225-53, xi	13
1137	Gliptins. 2007 , 369, 269	
1136	Stem/Progenitor cell sources of insulin-producing cells for the treatment of diabetes. 2007 , 13, 1399-412	64
1135	Management of Type 2 Diabetes Mellitus with Basal-Prandial Insulin Therapy: A Case-Based Review. 2007 , 2, 118-126	1
1134	Gut hormones, incretin mimetics and gliptins: new understanding and novel therapies in type 2 diabetes. 2007 , 1, 103-5	0
1133	Incretin hormone mimetics and analogues in diabetes therapeutics. 2007 , 21, 497-516	86
1132	Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. 2007 , 30, 1127-42	136

1131	Clinical and economic evaluation of exenatide for formulary decisions. 2007 , 10, 529-537	6
1130	Exenatide: a guide to its use as an adjunct to metformin and/or a sulfonylurea in patients with type 2 diabetes mellitus. 2007 , 23, 5-8	
1129	Impact of weight-loss medications on the cardiovascular system: focus on current and future anti-obesity drugs. 2007 , 7, 273-88	17
1128	Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control. 2007 , 23, 905-17	49
1127	Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies. 2007 , 23, 933-44	43
1126	Small-molecule agonists for the glucagon-like peptide 1 receptor. 2007 , 104, 937-42	186
1125	Le GLP-1 : de la physiologie à l'application thérapeutique. 2007 , 42, 199-206	
1124	Update on diabetes in the elderly and the application of current therapeutics. 2007 , 8, 489-92	37
1123	Metabolic syndrome and type 2 diabetes: can we stop the weight gain with diabetes?. 2007 , 91, 1107-23, ix	7
1122	Exenatide Quoi ? Comment ? Pour qui ?. 2007 , 1, 75-79	
1121	The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. 2007 , 9, 317-26	29
1120	[Incretins as new therapeutic targets of type 2 diabetes]. 2007 , 207, 352-64	0
1119	Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). 2007 , 67, 935-54	72
1118	Oral antidiabetic agents in type 2 diabetes. 2007 , 23, 945-52	68
1117	Appetite regulation: an overview. 2007 , 17, 433-45	86
1116	Exenatide. 2007 , 8, 2593-608	58
1115	Drug treatment of the overweight patient. 2007 , 132, 2239-52	102
1114	Biology of incretins: GLP-1 and GIP. 2007 , 132, 2131-57	2457

1113	Gut hormones regulating appetite and metabolism. 2007 , 4, 147-151	2
1112	When and how to restore β cell function?. 2007 , 1303, 138-145	1
1111	Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. 2007 , 23, 919-31	137
1110	Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. 2007 , 50, 6126-32	178
1109	Pharmacotherapeutic options for overweight adolescents. 2007 , 41, 1445-55	33
1108	[Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application]. 2007 , 148, 579-87	2
1107	Diabetes/Syndrome X. 2007 , 417-458	3
1106	The changing landscape of type 2 diabetes: the role of incretin-based therapies in managed care outcomes. 2007 , 13, S2-16; quiz S17	8
1105	Is exenatide improving the treatment of type 2 diabetes? Analysis of the individual clinical trials with exenatide. 2007 , 2, 77-84	4
1104	New therapeutic options for the management of diabetes. 2007 , 22, 45-56	5
1103	Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. 2007 , 13, 260-8	57
1102	Emerging treatments for patients with type 2 diabetes. 2007 , 33 Suppl 5, 105S-10S	1
1101	The role of self-monitoring of blood glucose during the treatment of type 2 diabetes with medications targeting postprandial hyperglycemia. 2007 , 100, 1123-31	2
1100	beta-cell function and anti-diabetic pharmacotherapy. 2007 , 23, 518-27	61
1099	The dipeptidyl-peptidase-4 (DPP-4) inhibitors: a new class of oral therapy for patients with type 2 diabetes mellitus. 2007 , 24, 474-482	6
1098	Treatment strategies for obesity. 2007 , 8 Suppl 1, 137-44	21
1097	Insulin-associated weight gain in diabetes--causes, effects and coping strategies. 2007 , 9, 799-812	351
1096	Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes. 2008 , 10, 18-33	16

1095	Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. 2007 , 9 Suppl 1, 23-31	54
1094	Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. 2008 , 10, 82-90	135
1093	Incretins and other peptides in the treatment of diabetes. 2007 , 24, 223-32	54
1092	Effect of renal impairment on the pharmacokinetics of exenatide. 2007 , 64, 317-27	169
1091	Diabetes mellitus and periodontal disease. 2007 , 44, 127-53	284
1090	Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. 2007 , 61, 29-37	27
1089	Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm. 2007 , 61, 3-11	13
1088	Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight. 2007 , 61, 19-28	28
1087	Pathophysiology and treatment of patients with type 2 diabetes exhibiting failure to oral drugs. 2008 , 192, 117-25	6
1086	A New Dawn for the Treatment of Type 2 Diabetes: Integrating Incretin Mimetics Into Clinical Practice. 2007 , 19, 1-24	1
1085	A New Dawn for the Treatment of Type 2 Diabetes: Integrating Incretin Mimetics Into Clinical Practice. 2007 , 19, 1-24	
1084	Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. 2007 , 99, 68B-79B	104
1083	The pathophysiology of cardiovascular disease in diabetes mellitus and the future of therapy. 2007 , 2, 108-13	24
1082	Mechanisms of action of glucagon-like peptide 1 in the pancreas. 2007 , 113, 546-93	463
1081	A Practical Guide for Aggressive Management of Type 2 Diabetes. 2007 , 3, 259-270	0
1080	New therapies for diabetes. 2007 , 8, 58-63; discussion 64-5	6
1079	Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. <i>Diabetes Care</i> , 2007 , 30, 1487-93	14.6 382
1078	A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. 2007 , 50, 259-67	380

1077	Comment on: Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50:259-267. 2007 , 50, 1561-2; author reply 1563-4	15
1076	Utilities and disutilities for type 2 diabetes treatment-related attributes. 2007 , 16, 1251-65	89
1075	Pharmacotherapy for obesity. 2007 , 9, 454-62	10
1074	GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors. 2007 , 7, 340-7	36
1073	Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity. 2007 , 7, 369-75	4
1072	Clinical experience with exenatide in predominantly Asian and Pacific Islander patients with type 2 diabetes. 2007 , 32, 311-6	3
1071	Current and novel therapies for the treatment of nonalcoholic steatohepatitis. 2007 , 1, 343-54	5
1070	Incretins: clinical physiology and bariatric surgery--correlating the entero-endocrine system and a potentially anti-dysmetabolic procedure. 2007 , 17, 569-76	10
1069	Inkretinmimetika und Inkretinverstärker. 2007 , 3, 387-398	1
1068	[New oral antidiabetic agents--clinical perspectives]. 2008 , 49, 495-501	4
1067	Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction. 2008 , 10, 55-60	32
1066	Combination pharmacotherapy with incretins: what works best and when?. 2008 , 8, 361-7	
1065	Glucagon-like peptide 1 based therapy for type 2 diabetes. 2008 , 4, 8-13	10
1064	Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom. 2008 , 7, 24	31
1063	Common crossroads in diabetes management. 2008 , 2, 4	4
1062	NICE gives rimonabant the green light. 2008 , 25, 302-304	
1061	Impact of therapeutic advances on hypoglycaemia in type 2 diabetes. 2008 , 24, 257-85	11
1060	Les incrétines. 2008 , 22, 59-65	

1059	Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. 2008 , 356, 231-8	66
1058	Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. 2008 , 24, 2943-52	321
1057	Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. 2008 , 11, 22-33	31
1056	The impact of body weight on patient utilities with or without type 2 diabetes: a review of the medical literature. 2008 , 11, 478-86	40
1055	Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects. 2008 , 10, 506-13	21
1054	Beyond insulin replacement: addressing the additional needs of the diabetes patient. 2008 , 10 Suppl 2, 83-97	5
1053	GLP-1: physiological effects and potential therapeutic applications. 2008 , 10, 994-1003	64
1052	Glucagon-like peptide-1-based therapies: new developments and emerging data. 2008 , 10, 22-35	9
1051	Hypoglycaemia in Type 2 diabetes. 2008 , 25, 245-54	372
1050	The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study. 2008 , 69, 737-44	49
1049	Gastrointestinal peptides controlling body weight homeostasis. 2008 , 155, 481-95	17
1048	Improving Insulin Sensitivity: A Review of New Therapies. 2008 , 9, S28-S38	
1047	Avances en el tratamiento de la diabetes mellitus tipo 2 y la enfermedad cardiovascular. 2008 , 8, 62C-72C	1
1046	Islet transplantation for brittle type 1 diabetes: the UIC protocol. 2008 , 8, 1250-61	142
1045	Inter-organ metabolic communication involved in energy homeostasis: potential therapeutic targets for obesity and metabolic syndrome. 2008 , 117, 188-98	33
1044	Prevention and treatment of type 2 diabetes: current role of lifestyle, natural product, and pharmacological interventions. 2008 , 118, 181-91	80
1043	Therapeutic management of posttransplant diabetes mellitus. 2008 , 22, 116-24	9
1042	The future of inhaled insulin and incretinmimetics in the management of diabetes. 2008 , 2, 59-61	2

1041	Gut hormones as potential new targets for appetite regulation and the treatment of obesity. 2008 , 68, 147-63	19
1040	New drugs for type 2 diabetes mellitus: what is their place in therapy?. 2008 , 68, 2131-62	82
1039	Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes. 2008 , 24, 2437-47	17
1038	Mechanisms of disease: the role of gastrointestinal hormones in appetite and obesity. 2008 , 5, 268-77	50
1037	An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. 2008 , 134, 1137-47	110
1036	Novedades en terapia hipoglucemiante. F�armacos con acci�n incretina. 2008 , 55, 73-77	
1035	Pancreatic Beta Cell in Health and Disease. 2008 ,	5
1034	Pharmacogenetics: potential role in the treatment of diabetes and obesity. 2008 , 9, 1109-19	11
1033	Medications for weight reduction. 2008 , 37, 923-42	19
1032	Prise de poids et traitements antidiab�tiques. 2008 , 2, 511-514	
1031	Perspectives des incr�tinomim�tiques. 2008 , 69, 77-78	
1030	Metformin therapy and clinical uses. 2008 , 5, 157-67	200
1029	New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. 2008 , 25, 913-25	51
1028	Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk. 2008 , 18, 639-45	44
1027	Differential inhibition of galanin- and ghrelin-induced food intake by i.c.v. GLP-1(7-36)-amide. 2008 , 147, 29-32	10
1026	[New therapies for type 2 diabetes: what place for incretin-based agents and rimonabant compared to the previous ones?]. 2008 , 29, 881-90	2
1025	Exendin-4 does not promote Beta-cell proliferation or survival during the early post-islet transplant period in mice. 2008 , 40, 1650-7	9
1024	Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. 2008 , 30, 858-67	42

1023	Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis. 2008 , 79, 196-203	52
1022	Effectiveness of the novel anti-diabetes medication exenatide in everyday practice: Comparison with clinical trials. 2008 , 80, e4-6	19
1021	Incretin-based therapies in type 2 diabetes: a review of clinical results. 2008 , 82 Suppl 2, S102-7	21
1020	Glucagon-like peptide-1 in type 2 diabetes: the cell and beyond. 2008 , 10, 2-13	11
1019	Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. 2008 , 372, 1240-50	848
1018	Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. 2008 , 24, 275-86	591
1017	Incorporating postprandial and fasting plasma glucose into clinical management strategies. 2008 , 3, 17-27	3
1016	Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies. 2008 , 34 Suppl 2, S78-90	20
1015	DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?. 2008 , 34 Suppl 2, S91-5	20
1014	Insulin resistance syndrome and glucose dysregulation in the elderly. 2008 , 24, 437-54, vi	2
1013	Incretin-based Therapies for Type 2 Diabetes. 2008 , 32, 131-9	15
1012	Exenatide: its position in the treatment of type 2 diabetes. 2008 , 69, 201-9	10
1011	Anti-obesity drugs. 2008 , 9, 1339-50	15
1010	Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes. 2008 , 9, 1705-20	17
1009	New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. 2008 , 117, 574-84	154
1008	Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. 2008 , 24, 639-44	28
1007	Analisi di costo-efficacia di exenatide versus insulina glargine nel trattamento dei pazienti diabetici di tipo 2 in fallimento secondario al doppio ipoglicemizzante orale. 2008 , 1, 21-30	2
1006	The role of incretins in glucose homeostasis and diabetes treatment. 2008 , 60, 470-512	552

1005	Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. 2008 , 57, 190-8	97
1004	Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. 2008 , 57, 2211-9	153
1003	Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK. 2008 , 24, 385-99	27
1002	Unmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents. 2008 , 31, 371-9	12
1001	Approaches to help people with diabetes overcome barriers for improved health outcomes. 2008 , 34 Suppl 1, 18S-24S	8
1000	Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?. 2008 , 158, 773-84	33
999	Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis. 2008 , 57, 1926-34	40
998	Incretin-based therapies in type 2 diabetes mellitus. 2008 , 93, 3703-16	159
997	The entero-insular axis: implications for human metabolism. 2008 , 46, 43-56	31
996	Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. 2008 , 29, 367-79	80
995	Incretin mimetics and enhancers for the treatment of type 2 diabetes mellitus. 2008 , 63, 81-5	2
994	Diabetes mellitus: considerations for dentistry. 2008 , 139 Suppl, 8S-18S	94
993	New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies. 2008 , 3 Suppl 2, S38-48	40
992	Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. 2008 , 61, 401-9	45
991	Increasing GLP-1-induced beta-cell proliferation by silencing the negative regulators of signaling cAMP response element modulator-alpha and DUSP14. 2008 , 57, 584-93	75
990	Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes. 2008 , 2, 255-60	15
989	Three new drugs for type 2 diabetes. 2008 , 46, 49-52	4
988	Acute exenatide (Byetta) poisoning was not associated with significant hypoglycemia. 2008 , 46, 346-7	8

987	Beyond glycaemic control: the effects of incretin hormones in type 2 diabetes. 2008 , 34 Suppl 3, 66S-72S	3
986	More choices than ever before: emerging therapies for type 2 diabetes. 2008 , 34, 518-34	27
985	Pharmacotherapy for obesity in menopausal women. 2008 , 14, 57-62	14
984	Recent advances in the management of type 2 diabetes mellitus: a review. 2008 , 84, 524-31	45
983	Pharmacology of GLP-1-based therapies. 2008 , 8, S10-S18	5
982	Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis. 2008 , 42, 1541-51	22
981	Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. 2008 , 93, 2670-8	144
980	The effects of pharmacologic agents for type 2 diabetes mellitus on body weight. 2008 , 120, 5-17	38
979	Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. 2008 , 17, 845-53	39
978	Verbesserung der Insulinsensitivität - Möglichkeiten und Grenzen der Pharmakotherapie. 2008 , 33, 62-69	
977	Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide. 2008 , 24, 3009-22	9
976	Hormone-based therapies in the regulation of fuel metabolism and body weight. 2008 , 8, 1733-47	11
975	Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. 2008 , 48, 1389-99	50
974	Exenatide: incretin therapy for patients with Type 2 diabetes mellitus. 2008 , 3, 671-690	4
973	Management of type 2 diabetes in the obese patient: current concerns and emerging therapies. 2008 , 24, 401-17	12
972	The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. 2008 , 86, 36-45	71
971	Insulin, other hypoglycemic drugs, and glucagon. 2008 , 494-506	
970	Management of Obesity. 2008 , 4, 122-130	1

969	Neuroendocrine regulation of food intake. 2008 , 24, 223-9	14
968	Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. 2008 , 4, 101-9	40
967	Introductory chapter. 1-19	
966	Potential therapies to limit obesity. 302-319	
965	Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. 2008 , 11, 491-9	76
964	[New therapies for diabetes: beyond injectable insulin and oral antidiabetics]. 2008 , 54, 447-54	1
963	Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease. 2008 , 4, 561-74	21
962	Objetivos moleculares para diseñar nuevos fármacos para el tratamiento de la diabetes tipo 2 y la obesidad. 2008 , 136,	3
961	Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. 2008 , 4, 383-94	55
960	Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. 2008 , 14, 285-92	69
959	Exenatide use in the management of metabolic syndrome: a retrospective database study. 2008 , 14, 993-9	20
958	Type I Allergy to Insulin: Case Report and Review of Localized and Systemic Reactions to Insulin. 2008 , 19, 52-58	6
957	Managed care perspective on three new agents for type 2 diabetes. 2008 , 14, 363-80	29
956	Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes. 2008 , 52, 1039-49	10
955	Can newer therapies delay the progression of type 2 diabetes mellitus?. 2008 , 14, 625-38	21
954	Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes. 2009 , Volume 2, 135-144	1
953	Efficacy and safety of incretin based therapies: clinical trial data. 2009 , 49 Suppl 1, S30-40	54
952	Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes. 2009 , 1, 1103-1119	1

951	Long-term metabolic and hormonal effects of exenatide on islet transplant recipients with allograft dysfunction. 2009 , 18, 1247-59		45
950	Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. 2009 , 5, 683-98		9
949	Alogliptin: a new addition to the class of DPP-4 inhibitors. 2009 , Volume 2, 117-126		29
948	Role and development of GLP-1 receptor agonists in the management of diabetes. 2009 , Volume 2, 37-49		12
947	The payer's dilemma: recognizing the uncertainty of clinical and economic evidence at product launch. 2009 , 15, 167-70		3
946	[Oral hypoglycaemic agents in 2009]. 2009 , 66, 677-84		2
945	Metformin: A Review of Its Use in the Treatment of Type 2 Diabetes. 2009 , 1, CMT.S1085		1
944	Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. 2009 , 49 Suppl 1, S16-29		101
943	Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. 2009 , 11, 353-9		23
942	Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. <i>Diabetes Care</i> , 2009 , 32, 1880-6	14.6	193
941	Exenatide improves hypertension in a rat model of the metabolic syndrome. 2009 , 7, 327-34		33
940	Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. 2009 , 76 Suppl 5, S28-38		48
939	Treating type 2 diabetes: incretin mimetics and enhancers. 2009 , 3, 387-95		5
938	Glucagon-like peptide 1 and pancreatic polypeptide responses to feeding in normal weight and overweight children. 2009 , 22, 493-500		6
937	Noncanonical activation of Akt/protein kinase B in {beta}-cells by the incretin hormone glucose-dependent insulinotropic polypeptide. 2009 , 284, 10764-73		23
936	Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. <i>Diabetes Care</i> , 2009 , 32, 1237-43	14.6	100
935	Review: Maximising the therapeutic potential of glucagon-like peptide-1 in type 2 diabetes. 2009 , 9, 44-52		2
934	New therapeutic horizons: mapping the future of glycemic control with incretin-based therapy. 2009 , 35, 731-4, 738-40, 742-4 passim		7

933	Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. 2009 , 160, 909-17	106
932	Expanding treatment options for type 2 diabetes: the old and the new. 2009 , 35 Suppl 1, 4S-11S	5
931	Results of the LEAD-2 study in relation to NICE and ADA/EASD guidelines for the treatment of type 2 diabetes in the UK. 2009 , 9, 177-185	1
930	Gastric electrical stimulation with the TANTALUS System in obese type 2 diabetes patients: effect on weight and glyceemic control. 2009 , 3, 964-70	36
929	Practical Use of Exenatide and Pramlintide for the Treatment of Type 2 Diabetes. 2009 , 22, 540-545	5
928	Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studies. 2009 , 121, 16-25	34
927	Minireview: Gut peptides: targets for antiobesity drug development?. 2009 , 150, 2526-30	41
926	Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. 2009 , 117, 522-57	74
925	Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge. 2009 , 37, 7-21	2
924	Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes. 2009 , 121, 46-58	14
923	Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. 2009 , 121, 5-15	23
922	Beyond glyceemic control: treating the entire type 2 diabetes disorder. 2009 , 121, 68-81	19
921	Recent advances in antidiabetic drug therapies targeting the enteroinsular axis. 2009 , 10, 125-37	39
920	Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2. 2009 , 4, 32-64	44
919	Promising strategies for obesity pharmacotherapy: melanocortin-4 (MC-4) receptor agonists and melanin concentrating hormone (MCH) receptor-1 antagonists. 2009 , 9, 504-38	19
918	Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in type 2 diabetic patients. 2009 , 41, 123-31	33
917	Nutrient-driven incretin secretion into intestinal lymph is different between diabetic Goto-Kakizaki rats and Wistar rats. 2009 , 296, G168-74	11
916	The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. 2009 , 121, 94-107	68

915	Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. 2009 , 22, 6-17		
914	Case Report. 2009 , 19, 119-121		3
913	Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes. <i>Diabetes Care</i> , 2009 , 32, 14-8	14.6	49
912	Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. 2009 , 27, 4-16		18
911	Novel Approaches to the Treatment of Type 2 Diabetes. 2009 , 22, 320-332		3
910	An update on preventive and regenerative therapies in diabetes mellitus. 2009 , 121, 317-31		36
909	Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. 2009 , 124, 113-38		143
908	Long-term benefits of insulin therapy and glycemic control in overweight and obese adults with type 2 diabetes. 2009 , 23, 143-52		6
907	Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus. 2009 , 29, 43S-54S		15
906	Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. 2009 , 31, 806-15		34
905	A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. 2009 , 31, 2472-88		81
904	Diabetes mellitus and gastric emptying: questions and issues in clinical practice. 2009 , 25, 502-14		35
903	Pharmacotherapy in pediatric obesity: current agents and future directions. 2009 , 10, 205-14		13
902	The role of incretins in cardiovascular control. 2009 , 11, 18-22		21
901	Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptor-mediated mechanism. 2009 , 13, 1762-72		101
900	Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy. 2009 , 26, 217-29		11
899	Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. 2009 , 52, 17-30		541
898	Perinatal survivin is essential for the establishment of pancreatic beta cell mass in mice. 2009 , 52, 2130-41		21

897	Exenatide initiation in type 2 diabetes: do more people discontinue treatment after individual rather than group starts?. 2009 , 26, 54-54	
896	Treatment options for type 2 diabetes:introducing the incretin-based therapies. 2009 , 26, 179-183ii	2
895	New treatments in type 2 diabetes: a focus on the incretin-based therapies. 2009 , 70, 343-53	36
894	Obesity treatment: novel peripheral targets. 2009 , 68, 830-43	49
893	Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. 2009 , 68, 861-74	65
892	Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. 2009 , 8, 369-85	323
891	Gut hormones and appetite control. 2009 , 15, 18-26	64
890	New developments in incretin-based therapies: the current state of the field. 2009 , 21 Suppl 1, 631-41	2
889	Optimizing outcomes with incretin-based therapies: practical information for nurse practitioners to share with patients. 2009 , 21 Suppl 1, 642-50	
888	Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists. 2009 , 63, 1154-60	35
887	Exenatide: a review from pharmacology to clinical practice. 2009 , 11, 544-56	86
886	Effect of antiobesity medications in patients with type 2 diabetes mellitus. 2009 , 11, 641-64	7
885	Long-term exendin-4 treatment delays natural deterioration of glycaemic control in diabetic Goto-Kakizaki rats. 2009 , 11, 884-90	6
884	The clinical challenges of managing type 2 diabetes and the potential of GLP-1-based therapies. 2009 , 11 Suppl 3, 1-3	1
883	Harnessing the weight-regulating properties of glucagon-like peptide-1 in the treatment of type 2 diabetes. 2009 , 11 Suppl 3, 4-10	2
882	The effects of glucagon-like peptide-1 on the beta cell. 2009 , 11 Suppl 3, 11-8	85
881	The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. 2009 , 11 Suppl 3, 26-34	172
880	Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. 2009 , 11, 1122-30	28

879	The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics. 2009 , 11, 1131-7		6
878	Exenatide efficacy and safety: a systematic review. 2009 , 26, 837-46		68
877	Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?. 2009 , 157, 1340-51		101
876	Pulmonary delivery of a GLP-1 receptor agonist, BMS-686117. 2009 , 366, 218-20		24
875	Exenatide once weekly for the treatment of type 2 diabetes. 2009 , 18, 359-67		35
874	One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. <i>Diabetes Care</i> , 2009 , 32, 762-8	14.6	327
873	Targeting the incretin system in type 2 diabetes mellitus. 2009 , 76, 244-56		3
872	Incretin-based therapies for type 2 diabetes mellitus. 2009 , 5, 262-9		510
871	Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. <i>Diabetes Care</i> , 2009 , 32, 84-90	14.6	882
870	Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. 2009 , 83, 69-76		74
869	GLP-1 receptor agonists: targeting both hyperglycaemia and disease processes in diabetes. 2009 , 85, 1-3		20
868	Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. 2009 , 20 Suppl 2, S329-39		33
867	Incretin therapies: effects beyond glycaemic control. 2009 , 20 Suppl 2, S319-28		16
866	Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. 2009 , 20 Suppl 2, S309-18		20
865	Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice. 2009 , 153, 70-6		28
864	The effect of exenatide re-exposure on safety and efficacy. 2009 , 30, 1771-4		21
863	Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. 2009 , 122, S11-24		41
862	Incretin therapies: effects beyond glycaemic control. 2009 , 122, S25-36		27

861	Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. 2009 , 122, S37-50		92
860	Pharmacologic management of the older patient with type 2 diabetes mellitus. 2009 , 7, 324-42		57
859	Dapagliflozin for the treatment of type 2 diabetes. 2009 , 43, 1286-93		21
858	Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. 2009 , 25, 3049-57		39
857	Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?. 2009 , 23, 513-23		15
856	Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. 2009 , 23, 463-77		100
855	Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. 2009 , 75, 1272-1277		227
854	Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , 2009 , 32, 193-203	14.6	2432
853	Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. 2009 , 58, 773-95		1832
852	Insulin Resistance. 2009 ,		
851	Diabetes medications and body weight. 2009 , 8, 573-84		93
850	Antidiabetic oral treatment in older people: does frailty matter?. 2009 , 26 Suppl 1, 53-62		26
849	Medications for obesity: mechanisms and applications. 2009 , 30, 525-38, ix		21
848	Pharmacotherapy of hyperglycemia. 2009 , 10, 2415-32		11
847	Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus. 2009 , 10, 135-42		32
846	Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. 2009 , 3, 245-59		56
845	Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide. 2009 , 86 Suppl 1, S26-34		22
844	Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. 2009 , 373, 473-81		837

843	Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). 2009 , 374, 39-47	1178
842	Synergistic weight loss and diabetes resolution with exenatide administration after laparoscopic gastric banding. 2009 , 5, 128-31	9
841	Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. 2009 , 18, 1495-503	62
840	Combination therapy for obesity and metabolic disease. 2009 , 16, 353-8	24
839	Cardiovascular manifestations of insulin resistance. 2009 , 16, e14-28	10
838	Liraglutide: a new treatment for type 2 diabetes. 2009 , 45, 101-13	29
837	Sir David Cuthbertson Medal Lecture. Bariatric surgery as a model to study appetite control. 2009 , 68, 227-33	8
836	Prise en charge thérapeutique du diabète de type 2. 2009 , 4, 1-7	
835	Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. 2009 , 56, 415-24	48
834	Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. 2009 , 56, 951-62	41
833	Future therapeutic directions; new medications and insulin delivery in a changing world for effective diabetes management. 2009 , 6, 200-13	2
832	Incretin-Based Therapies in Patients with Type 2 Diabetes. 2010 , 5, 75-85	
831	Preservation of beta-cell function in type 2 diabetes. 2010 , 16, 1038-55	17
830	Liraglutide, a GLP-1 Analogue to Treat Diabetes. 2010 , 333-357	2
829	Managing type 2 diabetes in the primary care setting: beyond glucocentricity. 2010 , 340, 133-43	4
828	The role of gut hormones and the hypothalamus in appetite regulation. 2010 , 57, 359-72	190
827	Weight management in type 2 diabetes mellitus. 2010 , 77, 533-48	12
826	New once-weekly formulation of exenatide for type 2 diabetes. 2010 , 11, 18-21	1

825	[Incretins: do they exert cardiovascular effects?]. 2010 , 35, 130-8	
824	[GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus]. 2010 , 105, 163-75	
823	The evolving place of incretin-based therapies in type 2 diabetes. 2010 , 25, 1207-17	25
822	Exenatide and weight loss. 2010 , 26, 243-9	49
821	New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier?. 2010 , 97, 63-83	56
820	Glycaemic control in type 2 diabetes: targets and new therapies. 2010 , 125, 328-61	130
819	Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. 2010 , 30, 609-24	43
818	Biological activity of EXf, a peptide analogue of exendin-4. 2010 , 628, 261-7	6
817	Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities. 2010 , 30, 463-549	72
816	Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. 2010 , 10, 20	69
815	Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. 2010 , 9, 45	36
814	[GLP-1 mimetics in clinical studies. Treatment by activation of the GLP-1 receptor]. 2010 , 39, 120-5	
813	New therapies for type 2 diabetes have added little to improve glycaemic control compared to conventional therapies. 2010 , 27, 72-74	
812	Exenatide associated renal failure. 2010 , 27, 232-234	7
811	A Practical Manual of Diabetes in Pregnancy. Edited by David McCance, Michael Maresh and David Sacks. © 2010, Wiley-Blackwell Price: ISBN: 9781405179041 website: www.wiley.com. 2010 , 27, 234-234	
810	The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4. 2010 , 160, 1973-84	24
809	Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy?. 2010 , 64, 791-801	23
808	The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes. 2010 , 64, 1402-14	31

807	Liraglutide: effects beyond glycaemic control in diabetes treatment. 2010 , 64, 28-34	11
806	Emerging treatment options for type 2 diabetes. 2010 , 70, 631-44	42
805	Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay. 2010 , 12, 267-87	63
804	Diabesity: therapeutic options. 2010 , 12, 463-73	81
803	Glycaemic goals in patients with type 2 diabetes: current status, challenges and recent advances. 2010 , 12, 474-84	21
802	Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. 2010 , 12, 341-7	78
801	A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. 2010 , 12, 1058-65	56
800	In support of an early polypharmacy approach to the treatment of type 2 diabetes. 2010 , 12, 929-40	20
799	Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. 2010 , 27, 309-17	158
798	Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. 2010 , 27, 1024-32	125
797	Prophylactic use of anti-emetic medications reduced nausea and vomiting associated with exenatide treatment: a retrospective analysis of an open-label, parallel-group, single-dose study in healthy subjects. 2010 , 27, 1168-73	19
796	Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide. 2010 , 6, 401-11	19
795	Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus. 2010 , Volume 3, 165-172	
794	Diabetes: 75-82	
793	Exenatide once weekly: clinical outcomes and patient satisfaction. 2010 , 4, 313-24	10
792	Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies. 2010 , Volume 3, 227-242	3
791	Managing diabetes with new pharmaceutical agents. 2010 , 21, 634-638	
790	Tackling obesity: new therapeutic agents for assisted weight loss. 2010 , Volume 3, 95-112	5

789	Pediatric Dosing and Body Size in Biotherapeutics. 2010 , 2, 389-418	25
788	The continuation of oral medications with the initiation of insulin therapy in type 2 diabetes: a review of the evidence. 2010 , 103, 58-65	13
787	Emerging role of GLP-1 receptor agonists in the treatment of obesity. 2010 , Volume 3, 263-273	8
786	Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review. 2010 , Volume 3, 155-163	16
785	Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. 2010 , 6, 541-8	80
784	Exenatide Use in the Management of Type 2 Diabetes Mellitus. 2010 , 3, 2554-2567	11
783	Abstracts of the 19th Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists. April 21-25, 2010. Boston, Massachusetts, USA. 2010 , 16 Suppl 2, 1-49	1
782	Exenatide-induced acute pancreatitis. 2010 , 16, 80-3	37
781	A Review of Exenatide in the Treatment of Type 2 Diabetes Mellitus. 2010 , 2, CMT.S3489	
780	A practical Guide to Treatment with Liraglutide. 2010 , 2, CMT.S4148	1
779	GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene. 2010 , 51, 3145-57	69
778	Current developments in the treatment of diabetes: the incretin therapies. 2010 , 10, 21-30	1
777	Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. 2010 , 23, 334-9	153
776	Treatment of diabetes with glucagon-like peptide-1 gene therapy. 2010 , 10, 1681-92	11
775	Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes. 2010 , 10, 801-6	46
774	Roles of gastrointestinal and adipose tissue peptides in childhood obesity and changes after weight loss due to lifestyle intervention. 2010 , 164, 131-8	44
773	The evolving world of GLP-1 agonist therapies for type 2 diabetes. 2010 , 1, 61-7	2
772	Brain imaging studies of appetite in the context of obesity and the menstrual cycle. 2010 , 16, 276-92	47

771 Medications. **2010**, 26, 193-213

770	A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. 2010 , 86, 44-57		96
769	Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. <i>Diabetes Care</i> , 2010 , 33, 1300-3	14.6	153
768	Liraglutide: a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus. 2010 , 67, 1326-36		9
767	Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. 2010 , 14, 1-248		99
766	Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action. 2010 , 3, 3005-3020		67
765	Weight Management in Overweight and Obese Patients with Type 2 Diabetes Mellitus. 2010 , 10, 274-283		12
764	Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial). 2010 , 11, 2269-71		8
763	The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review. 2010 , 12, 11-24		29
762	Effectiveness of exenatide in Asian Indians in a clinical care setting. 2010 , 12, 613-8		4
761	Diabetes Treatment: Insulin and Incretins. 2010 , 28, 177-182		1
760	DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. <i>Diabetes Care</i> , 2010 , 33, 1255-61	14.6	274
759	Understanding GLP-1 analogs and enhancing patients success. 2010 , 36 Suppl 3, 44S-72S; quiz 73S-74S		14
758	The incretin system in the management of type 2 diabetes mellitus. 2010 , 10, 491-5		1
757	New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals. 2010 , 122, 52-60		16
756	Introduction - obesity and food intake: basic and clinical approaches. 2010 , 63, 1-8		
755	Can therapies that target the incretin system improve our ability to treat type 2 diabetes?. 2010 , 102, 511-23		5
754	Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes. 2010 , 122, 172-83		7

753	How to obtain appropriate type 2 diabetes control in the first 180 days of treatment initiation. 2010 , 122, 33-42	3
752	Incretin-based therapies for type 2 diabetes: a nurse's perspective. 2010 , 19, 1337-8, 1340-4	1
751	Type 2 diabetes and obesity in adults. 2010 , 19, 880, 882-6	24
750	Overcoming challenges in Type 2 diabetes management to improve patient outcomes. 2010 , 5, 741-751	1
749	Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes. 2010 , 122, 118-28	26
748	Contemporary management of patients with Type 2 diabetes. 2010 , 8, 767-70	
747	Gestione terapeutica del diabete di tipo 2. 2010 , 12, 1-7	
746	Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitus. 2010 , 85, S38-49	14
745	Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors. 2010 , 85, S27-37	39
744	Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. 2010 , 26, 331-338	24
743	Clinical approaches to preserve beta-cell function in diabetes. 2010 , 654, 515-35	28
742	Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide. 2010 , 50, 886-94	32
741	Non-Insulin Parenteral Therapies. 2010 , 478-493	1
740	Clinical experience with exenatide in a routine secondary care diabetes clinic. 2010 , 4, 57-60	3
739	Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus. 2010 , 33, 87-100	19
738	Association of pancreatitis with glucagon-like peptide-1 agonist use. 2010 , 44, 904-9	61
737	Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity. 2010 , 36, 293-8	23
736	One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. 2010 , 36, 381-8	37

735	Functional coupling of Cys-226 and Cys-296 in the glucagon-like peptide-1 (GLP-1) receptor indicates a disulfide bond that is close to the activation pocket. 2010 , 31, 2289-93	17
734	Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides. 2010 , 92, 442-62	101
733	Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. 2010 , 123, 468.e9-17	75
732	Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. 2010 , 123, S19-27	52
731	Incretin-based therapies: review of current clinical trial data. 2010 , 123, S28-37	88
730	Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going. 2010 , 123, S38-48	87
729	Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies. 2010 , 123, S2-S10	26
728	Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure. 2010 , 1, 24-36	10
727	Combination treatment of db/db mice with exendin-4 and gastrin preserves β cell mass by stimulating β cell growth and differentiation. 2010 , 1, 172-83	16
726	Tratamiento de la diabetes de tipo 2. 2010 , 14, 1-7	
725	[Safety and tolerability of oral antidiabetes drugs in the treatment of type 2 diabetes mellitus]. 2010 , 135 Suppl 2, 20-6	0
724	Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. 2010 , 375, 1447-56	485
723	Addition of incretin therapy to metformin in type 2 diabetes. 2010 , 375, 1410-2	34
722	Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. 2010 , 375, 2234-43	365
721	Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. 2010 , 376, 431-9	503
720	Longacting exenatide in diabetes: DURATION-3. 2010 , 375, 2198-9	2
719	Combinations of drugs in the Treatment of Obesity. 2010 , 3, 2398-2415	18
718	The incretin system and cardiometabolic disease. 2010 , 26, 87-95	10

717	The role of GLP-1 in neuronal activity and neurodegeneration. 2010 , 84, 331-54	47
716	Comparativa entre los diversos tratamientos de la hiperglucemia: estrategias para minimizar la ganancia ponderal en la diabetes tipo 2. 2010 , 26, 156-160	1
715	Analisi economica di exenatide rispetto a liraglutide nei pazienti con diabete di tipo 2: costo-efficacia e budget impact. 2010 , 3, 73-79	
714	Ketoconazole enantiomer for the treatment of diabetes mellitus. 2010 , 19, 185-94	17
713	Exenatide versus glibenclamide in patients with diabetes. 2010 , 12, 233-40	97
712	Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting. 2011 , 27, 2335-42	14
711	Valutazione economica del trattamento con exenatide o sitagliptin di pazienti affetti da diabete tipo 2 in Italia. 2011 , 4, 1-6	2
710	Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting. 2011 , 27, 531-40	4
709	Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies. 2011 , 34, 69-77	18
708	Tailoring treatment for type 2 diabetes: Uncovering the HOW and NOW of GLP-1 receptor agonist therapy. 2011 , 3, 217-236	1
707	Preservation of β cell function: the key to diabetes prevention. 2011 , 96, 2354-66	182
706	Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes. 2011 , 58, 112-120	6
705	[Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes]. 2011 , 58, 112-20	9
704	Type 2 Diabetes in Adults. 2011 , 77-137	3
703	Incretin-based therapies and their future in Type 2 diabetes mellitus. 2011 , 8, 143-152	1
702	Add-on therapies to metformin for type 2 diabetes. 2011 , 12, 47-62	14
701	Medications for weight reduction. 2011 , 95, 989-1008	6
700	Dipeptidyl Peptidase IV Inhibitors for Treatment of Diabetes. 2011 , 327-358	2

699	Emerging GLP-1 receptor agonists. 2011 , 16, 607-18	20
698	Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. 2011 , 50, 65-74	103
697	Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents. 2011 , 71, 1675-88	63
696	GLP-1 and energy balance: an integrated model of short-term and long-term control. 2011 , 7, 507-16	147
695	New drug targets for the treatment of obesity. 2011 , 90, 40-51	94
694	Choosing targets for glycaemia, blood pressure and low-density lipoprotein cholesterol in elderly individuals with diabetes mellitus. 2011 , 28, 945-60	13
693	Metabolic Basis of Obesity. 2011 ,	3
692	Achieving a successful pregnancy in women with polycystic ovary syndrome. 2011 , 40, 865-94	5
691	Pharmacological management of type 2 diabetes mellitus: an update. 2011 , 7, 392-405	54
690	Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. 2011 , 23, 40-48	
689	Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. 2011 , 124, S3-18	220
688	Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time?. 2011 , 124, S19-34	54
687	Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies. 2011 , 124, S35-53	58
686	Incretin-based therapies in complex patients: practical implications and opportunities for maximizing clinical outcomes: a discussion with Dr. Vivian A. Fonseca. 2011 , 124, S54-61	15
685	Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. 2011 , 37, 477-88	38
684	GLP-1 receptor agonists today. 2011 , 93, 317-27	17
683	Weight beneficial treatments for type 2 diabetes. 2011 , 96, 3337-53	72
682	Management of type 2 diabetes mellitus in the elderly. 2011 , 70, 151-9	30

681	Emerging therapies in the treatment of 'diabesity': beyond GLP-1. 2011 , 32, 8-15	32
680	Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. 2011 , 37, 74-82	1
679	Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. 2011 , 2, 210-7	43
678	Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes. 2011 , 2, 448-56	12
677	Glucagón: ¿un simple espectador o un jugador clave en la fisiopatología de la diabetes?. 2011 , 27, 160-167	
676	Incretin effect: GLP-1, GIP, DPP4. 2011 , 93 Suppl 1, S32-6	52
675	Glucolipototoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy?. 2011 , 93 Suppl 1, S37-46	52
674	The Current Status of Exenatide Once Weekly. 2011 , 3, CMT.S3083	4
673	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. 2011 , 17 Suppl 2, 1-53	329
672	Role of Incretin, Incretin Analogues and Dipeptidyl Peptidase 4 Inhibitors in the Pathogenesis and Treatment of Diabetes Mellitus. 2011 ,	
671	. 2011 ,	1
670	GLP-1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies. 2011 , 279-325	
669	The results of prolonged action of GLP-1 on some metabolic parameters. 2011 , 59, 13-7	1
668	Present and future: pharmacologic treatment of obesity. 2011 , 2011, 636181	36
667	Weight considerations in pharmacotherapy for type 2 diabetes. 2011 , 2011,	21
666	Hypothalamic obesity in patients with craniopharyngioma: profound changes of several weight regulatory circuits. 2011 , 2, 49	29
665	Advances in the treatment of type 2 diabetes mellitus. 2011 , 18, 117-52	112
664	The gut hormones in appetite regulation. 2011 , 2011, 528401	52

663	Pharmacotherapy for obesity: a field in crisis?. 2011 , 6, 563-577	4
662	Pharmacological management of type 2 diabetes: the potential of incretin-based therapies. 2011 , 13, 99-117	30
661	Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. 2011 , 13, 207-20	55
660	Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. 2011 , 13, 302-12	104
659	LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. 2011 , 13, 434-8	59
658	Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*. 2011 , 13, 703-10	73
657	Current and emerging antiglycaemic pharmacological therapies: the renal perspective. 2011 , 16, 468-75	8
656	Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential. 2011 , 12, 593-601	40
655	Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity. 2011 , 163, 399-412	42
654	Effective and safe gene-based delivery of GLP-1 using chitosan/plasmid-DNA therapeutic nanocomplexes in an animal model of type 2 diabetes. 2011 , 18, 807-16	36
653	Update on incretin hormones. 2011 , 1243, E55-74	88
652	Antibodies in metabolic diseases. 2011 , 28, 530-7	10
651	[Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes]. 2011 , 211, 147-55	12
650	Beyond metformin: initiating combination therapy in patients with type 2 diabetes mellitus. 2011 , 31, 44S-53S	13
649	Liraglutide: clinical pharmacology and considerations for therapy. 2011 , 31, 896-911	17
648	A review of diabetes treatment adherence and the association with clinical and economic outcomes. 2011 , 33, 74-109	280
647	Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success. 2011 , 33, 408-24	22
646	Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. 2011 , 33, 528-76	39

645	Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes. 2011 , 33, 665-78	47
644	Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents. 2011 , 33, 1698-712	18
643	[Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes]. 2011 , 43, 202.e1-9	9
642	Emerging pharmacotherapy for obesity. 2011 , 16, 587-96	20
641	Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. 2011 , 45, 850-60	45
640	Effects of glucose-lowering drugs on body weight in type 2 diabetes. 2011 , 22, 32-42	
639	Is the GLP-1 system a viable therapeutic target for weight reduction?. 2011 , 12, 187-95	15
638	Metabolic surgery-principles and current concepts. 2011 , 396, 949-72	24
637	Molecular modeling of lanthionine synthetase component C-like protein 2: a potential target for the discovery of novel type 2 diabetes prophylactics and therapeutics. 2011 , 17, 543-53	29
636	Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets. 2011 , 54, 1756-65	44
635	Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. 2011 , 2, 101-21	76
634	Diabetes and cardiovascular disease: the potential benefit of incretin-based therapies. 2011 , 13, 115-22	23
633	Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. 2011 , 11, 9	56
632	Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. 2011 , 10, 22	124
631	The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. 2011 , 27, 528-42	75
630	Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects. 2011 , 96, 1763-70	41
629	Potential use of exenatide for the treatment of obesity. 2011 , 20, 1717-22	9
628	Liraglutide for type 2 diabetes mellitus. 2011 , 11, 951-9	3

627	The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. 2011 , 123, 189-201	25
626	Bombesin receptor subtype-3 (BRS-3) regulates glucose-stimulated insulin secretion in pancreatic islets across multiple species. 2011 , 152, 4106-15	38
625	Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. 2011 , 39, 7-21	36
624	Utilizing current diagnostic criteria and treatment algorithms for managing type 2 diabetes mellitus. 2011 , 123, 54-62	7
623	Effect of administration time of exenatide on satiety responses, blood glucose, and adverse events in healthy volunteers. 2011 , 51, 165-72	15
622	Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. 2011 , 96, 1695-702	106
621	Glycemic control impact on body weight potential to reduce cardiovascular risk: glucagon-like peptide 1 agonists. <i>Diabetes Care</i> , 2011 , 34 Suppl 2, S272-5	14.6 3
620	GLP-1 receptor agonists and HBA1c target of . 2011 , 27, 1519-28	37
619	DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. 2011 , 96, 1301-10	346
618	Polypharmacy and renal failure. 2011 , 11, 150-152	1
617	Adipocyte expression of the glucose-dependent insulinotropic polypeptide receptor involves gene regulation by PPAR α and histone acetylation. 2011 , 52, 759-70	38
616	Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. 2011 , 2011, 215764	85
615	From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy. 2011 , 2011, 898913	15
614	The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus. 2011 , 4, 13-24	2
613	Incretin-Related Therapies in Type 2 Diabetes: A Practical Overview. 2011 , 24, 26-35	5
612	Comparative efficiency and safety of pharmacological approaches to the management of obesity. <i>Diabetes Care</i> , 2011 , 34 Suppl 2, S349-54	14.6 8
611	Incretin effects on β -cell function, replication, and mass: the human perspective. <i>Diabetes Care</i> , 2011 , 34 Suppl 2, S258-63	14.6 71
610	Glucagon-like peptide-1 analogs in the treatment of Type 2 diabetes: a review of the Phase II and III trials. 2011 , 1, 327-343	1

609	Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus. 2011 , 13, 143-8	59
608	Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. <i>Diabetes Care</i> , 2011 , 34 Suppl 2, S279-84	14.6 235
607	Review of approved pioglitazone combinations for type 2 diabetes. 2011 , 12, 1571-84	9
606	Diabetes mellitus: new drugs for a new epidemic. 2011 , 107, 65-73	48
605	Management of Pediatric Obesity and Diabetes. 2011 ,	3
604	Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4. 2011 , 301, R1011-24	56
603	Focus on incretin-based therapies: targeting the core defects of type 2 diabetes. 2011 , 123, 53-65	14
602	The fetal origins of the metabolic syndrome: can we intervene?. 2012 , 2012, 482690	11
601	Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence. 2012 , 30, 3-12	24
600	Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies. 2012 , 3, 185-201	4
599	What have we learned about the treatment of type 2 diabetes? The evolving paradigms. 2012 , 19, 449-64	2
598	Drug-drug interactions with glucagon-like peptide-1 receptor agonists. 2012 , 46, 710-7	17
597	Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. 2012 , 124, 21-32	33
596	Effects of exenatide in poorly controlled type 2 diabetes. 2012 , 105, 321-6	4
595	Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naïve, newly diagnosed type 2 diabetes mellitus. 2012 , 97, E1720-5	73
594	Glucagon-like Peptide-1 (GLP-1): 25 Jahre Ansporn für die Diabetesforschung. 2012 , 7, 367-372	
593	Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?. 2012 , 44, 338-49	7
592	Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany. 2012 , 15, 746-57	8

591	Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. <i>Diabetes Care</i> , 2012 , 35, 1446-54	14.6	133
590	βcell preservation and regeneration for diabetes treatment: where are we now?. 2012 , 2, 213-222		3
589	Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. <i>Diabetes Care</i> , 2012 , 35, 4-11	14.6	161
588	GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. 2012 , 9, 95-108		67
587	Obesity, a health burden of a global nature. 2012 , 33, 145-7		33
586	A therapeutic approach to hyperglycaemia in the setting of acute myocardial infarction: spotlight on glucagon-like peptide 1. 2012 , 6, 213-9		3
585	Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. <i>Diabetes Care</i> , 2012 , 35, 1986-93	14.6	50
584	Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus. 2012 , 46, 812-21		13
583	Safety and tolerability of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. 2012 , 12, 6-16		1
582	Managing diabetes from first diagnosis: choosing well-tolerated therapies with durability. 2012 , 38, 4S-11S; quiz 12S		5
581	Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis. 2012 , 2012, 230624		28
580	Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. 2012 , 2012, 672658		61
579	Obesity and appetite control. 2012 , 2012, 824305		132
578	Cardiovascular benefits of GLP-1-based therapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control. 2012 , 2012, 635472		28
577	Roles of Glucagon-Like Peptide and Glucose-Dependent Insulinotropic Polypeptide Hormones in Brain Function and Neurodegeneration. 2012 , 351-373		
576	Determining predictors of response to exenatide in type 2 diabetes. 2012 , 52, 466-71		21
575	Successful treatment of prediabetes in clinical practice: targeting insulin resistance and βcell dysfunction. 2012 , 18, 342-50		29
574	Exenatide: role in management of Type 2 diabetes and associated cardiovascular risk factors. 2012 , 9, 23-38		

573	Investigation of transport mechanism of exendin-4 across Madin Darby canine kidney cell monolayers. 2012 , 35, 745-52	7
572	Recent advances in incretin-based therapies. 2012 , 77, 489-99	54
571	Exenatide as a novel weight loss modality in patients without diabetes. 2012 , 46, 1700-6	9
570	Small molecule allosteric modulation of the glucagon-like Peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin. 2012 , 82, 1066-73	44
569	Management of diabetes in primary care: individualisation of care. 2012 , 29, 331-334a	2
568	Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects. 2012 , 179, 77-83	33
567	The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. 2012 , 14, 561-7	52
566	The role of the gut/brain axis in modulating food intake. 2012 , 63, 46-56	107
565	The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. 2012 , 62, 1916-27	185
564	GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. 2012 , 8, 728-42	744
563	Incretin-based Therapies (Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors) for the Treatment of Type 2 Diabetes. 2012 , 36, 9-14	3
562	Two small molecule agonists of glucagon-like peptide-1 receptor modulate the receptor activation response differently. 2012 , 417, 558-63	13
561	An overview of the pharmacokinetics, efficacy and safety of liraglutide. 2012 , 97, 27-42	53
560	Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial. 2012 , 12, 8	18
559	Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. 2012 , 36, 909-21	73
558	Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy. 2012 , 66, 1147-57	12
557	Exenatide plus metformin compared with metformin alone on β cell function in patients with Type 2 diabetes. 2012 , 29, 1515-23	48
556	A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes. 2012 , 13, 1451-67	21

555	Novel GLP-1 receptor agonists for diabetes. 2012 , 21, 45-57	54
554	Newer Diabetes Medications. 2012 , 375-417	
553	Alterations in energy balance following exenatide administration. 2012 , 37, 893-9	33
552	Synthesis and structure-activity relationship of fused-pyrimidine derivatives as a series of novel GPR119 agonists. 2012 , 20, 6442-51	13
551	Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study. 2012 , 34, 1892-908.e1	63
550	Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes. 2012 , 38, 298-308	11
549	Manejo terapéutico de la hiperglucemia en la diabetes tipo 2. Antidiabéticos orales. 2012 , 11, 1073-1081	
548	Recomendaciones para el empleo de antidiabéticos orales en la diabetes tipo 2. 2012 , 11, 1112-1116	
547	[Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide]. 2012 , 139, 572-8	3
546	A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. 2012 , 98, 271-84	117
545	Exenatide, a GLP-1 agonist in the treatment of Type 2 diabetes. 2012 , 7, 15-26	6
544	An update in incretin-based therapy: a focus on glucagon-like peptide-1 receptor agonists. 2012 , 14, 951-67	23
543	Treatment with glucagon-like Peptide-1 agonist exendin-4 in a patient with hypothalamic obesity secondary to intracranial tumor. 2012 , 78, 54-8	21
542	A continued saga of Boc5, the first non-peptidic glucagon-like peptide-1 receptor agonist with in vivo activities. 2012 , 33, 148-54	24
541	Efficacy and safety of tasoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial). 2012 , 3, 13	35
540	Liraglutide in Combination with Metformin or Sulfonylurea for the Treatment of Type 2 Diabetes in Adult patients. 2012 , 4, CMT.S7283	
539	Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide. 2012 , 18, e10-3	34
538	Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide. 2012 , 18, 227-37	11

537	The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analysis of randomized clinical trials. 2012 , 15, 1-30	20
536	Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States. 2012 , 18, 700-11	5
535	Nutrology and type 2 diabetes: Nutrient pathophysiology and the transition from health to disease. 2012 , 05, 006-013	1
534	Incretin-based therapies for type 2 diabetes. 2012 , 23, 508-515	
533	Incretin therapies for type 2 diabetes: what nurses need to know. 2012 , 10, 345-352	
532	Incretin-based therapies for type 2 diabetes. 2012 , 10, 184-188	
531	Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. 2012 , 5, 29-41	33
530	Exendin-4 improves resistance to <i>Listeria monocytogenes</i> infection in diabetic db/db mice. 2012 , 13, 245-52	
529	Novel pharmacological approaches to the treatment of type 2 diabetes. 2012 , 64, 188-237	70
528	The effect of glucagon-like peptide 1 on cardiovascular risk. 2012 , 9, 209-22	117
527	Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. <i>Diabetes Care</i> , 2012 , 35, 683-9	14.6 80
526	A review of exenatide: optimizing glycemic control and associated cardiovascular risk factors in type 2 diabetes. 2012 , 3, 1-16	5
525	Incretin-based therapies. 2012 , 4, 55-67	29
524	Effects of incretins on blood pressure: a promising therapy for type 2 diabetes mellitus with hypertension. 2012 , 4, 22-9	7
523	Using albumin to improve the therapeutic properties of diabetes treatments. 2012 , 14, 121-9	8
522	Effect of exenatide, pen insulin, and vial insulin on patient outcomes: a retrospective database analysis of persistence and first-year costs in a commercially insured population. 2012 , 34, 1145-58	1
521	Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review. 2012 , 34, 1221-36	47
520	Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. 2012 , 34, 1247-1258.e22	200

519	Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary. 2012 , 34, 1301-13	3
518	Chitosan-based therapeutic nanoparticles for combination gene therapy and gene silencing of in vitro cell lines relevant to type 2 diabetes. 2012 , 45, 138-49	51
517	Insulin initiation in type 2 diabetes: what are the treatment regimen options and how can we best help patients feel empowered?. 2012 , 24 Suppl 1, 249-59	10
516	Functional importance of GLP-1 receptor species and expression levels in cell lines. 2012 , 175, 21-9	22
515	The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent. 2012 , 59, 464-71	96
514	Impact of postprandial glycaemia on health and prevention of disease. 2012 , 13, 923-84	232
513	The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review. 2012 , 14, 387-98	13
512	Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs. 2012 , 14, 424-32	38
511	GLP-1 based therapies: differential effects on fasting and postprandial glucose. 2012 , 14, 675-88	91
510	Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. 2012 , 14, 546-54	113
509	The design of the liraglutide clinical trial programme. 2012 , 14 Suppl 2, 4-12	8
508	Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents. 2012 , 14 Suppl 2, 20-32	18
507	Clinical considerations for the management of residual diabetes following bariatric surgery. 2012 , 14, 773-79	16
506	Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide. 2012 , 14 Suppl 2, 41-9	20
505	Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. 2012 , 14, 762-7	147
504	Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. 2012 , 14, 810-20	126
503	Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus. 2012 , 4, 8	13
502	Advances in medical therapy for weight loss and the weight-centric management of type 2 diabetes mellitus. 2012 , 14, 60-9	20

501	Impact of Newer Medications for Type 2 Diabetes on Body Weight. 2013 , 2, 134-141	7
500	Current issues in GLP-1 receptor agonist therapy for type 2 diabetes. 2012 , 18 Suppl 3, 6-26; quiz 27-8	6
499	Lipids, CHOs, proteins: can all macronutrients put a 'brake' on eating?. 2013 , 120, 114-23	62
498	Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. 2013 , 381, 117-24	397
497	Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals. 2013 , 12, 48	15
496	The Incretin Mimetics. 2013 , 20-32	
495	Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?. 2013 , 44, 47-58	28
494	Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?. 2013 , 56, 1878-83	34
493	Complementing insulin therapy to achieve glycemic control. 2013 , 30, 557-76	28
492	Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus. 2013 , 39, 485-96	59
491	Design, synthesis, and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates. 2013 , 56, 9955-68	52
490	Complications of diabetes therapy. 2013 , 42, 947-70	16
489	Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy. 2013 , 58, 38-43	4
488	The cardiovascular safety of incretin-based therapies: a review of the evidence. 2013 , 12, 130	33
487	Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study. 2013 , 13, 20	8
486	Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE. 2013 , 4, 285-308	10
485	Incretin-based therapies: focus on effects beyond glycemic control alone. 2013 , 4, 221-38	12
484	Effect of chitosan on physicochemical properties of exenatide-loaded PLGA nanoparticles. 2013 , 43, 489-497	9

483	Voltage-gated proton channels: molecular biology, physiology, and pathophysiology of the H(V) family. 2013 , 93, 599-652	152
482	Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus. 2013 , 4, 182-9	11
481	GLP-1 receptor activated insulin secretion from pancreatic β cells: mechanism and glucose dependence. 2013 , 15, 15-27	193
480	Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. 2013 , 15, 42-54	74
479	Contribution of insulin deficiency and insulin resistance to the development of type 2 diabetes: nature of early stage diabetes. 2013 , 50, 39-45	24
478	Glucagon-like peptide-1 reduces contractile function and fails to boost glucose utilization in normal hearts in the presence of fatty acids. 2013 , 168, 4085-92	12
477	Incretin-based therapies in the treatment of type 2 diabetes--more than meets the eye?. 2013 , 24, 207-12	35
476	Successful Primary Care Management of Type II DiabetesContents. 2013 , 4-111	
475	New incretin hormonal therapies in humans relevant to diabetic cats. 2013 , 43, 417-33	4
474	Safety and efficacy of twice-daily exenatide in Taiwanese patients with inadequately controlled type 2 diabetes mellitus. 2013 , 112, 144-50	12
473	Advances in pharmacologic therapies for type 2 diabetes. 2013 , 15, 302	13
472	A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo. 2013 , 15, 213-23	43
471	Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension. 2013 , 15, 14-33	251
470	Differentiation of human adipose-derived mesenchymal stem cell into insulin-producing cells: an in vitro study. 2013 , 69, 451-8	37
469	Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013. 2013 , 5, 241-53	8
468	Diabetes Drugs. 2013 , 205-243	
467	The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists. 2013 , 13, 307-18	20
466	Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors. 2013 , 47, 490-505	28

465	Reducing the risk of obesity: defining the role of weight loss drugs. 2013 , 33, 1308-21	11
464	Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes. 2013 , 15, 593-606	38
463	Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. 2013 ,	
462	Pharmacology, Biodiversity and. 2013 , 703-715	
461	Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus. 2013 , 14, 2281-96	19
460	Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes. 2013 , 29, 1617-26	11
459	Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice. 2013 , 19, 718-28	7
458	Parkinson's disease, insulin resistance and novel agents of neuroprotection. 2013 , 136, 374-84	180
457	GLP-1 receptor agonists in the treatment of Type 2 diabetes. 2013 , 3, 401-413	12
456	Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach. 2013 , 125, 112-26	9
455	Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. 2013 , 3,	207
454	Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. 2013 , 14, 22933-66	72
453	Medicinal chemistry of glucagon-like peptide receptor agonists. 2013 , 52, 45-96	9
452	Mechanism of metabolic advantages after bariatric surgery: it's all gastrointestinal factors versus it's all food restriction. <i>Diabetes Care</i> , 2013 , 36 Suppl 2, S287-91	14.6 55
451	Combining incretin-based therapies with insulin: realizing the potential in type 2 diabetes. <i>Diabetes Care</i> , 2013 , 36 Suppl 2, S226-32	14.6 40
450	Exenatide extended-release; clinical trials, patient preference, and economic considerations. 2013 , 7, 35-45	6
449	Incretin-based therapy for type 2 diabetes mellitus: pancreatic and extrapancreatic effects. 2013 , 20, 384-93	4
448	Non-insulin treatments for diabetes. 2013 , 20, 377-84	2

447	Recent and emerging therapeutic medications in type 2 diabetes mellitus: incretin-based, Pramlintide, Colesevelam, SGLT2 Inhibitors, Tagatose, Succinobucol. 2013 , 20, 638-53		8
446	Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research. 2013 , 10, 72-7		51
445	Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature. 2013 , 8, 247-259		18
444	Glucagon-like peptide-1 analogues: An overview. 2013 , 17, 413-21		86
443	Aliskiren, exendin-4, and insulin: their impact on endothelin receptor subtype(s) regulation/binding in type 1 diabetic rat hearts. 2013 , 91, 830-8		2
442	Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. 2013 , 10, 31-36		8
441	Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus. 2013 , 4, 53-61		66
440	Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment--a position paper of the The Obesity Society and The American Society of Hypertension. 2013 , 21, 8-24		155
439	Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit. 2013 , 19, 81-90		41
438	Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy. 2013 , 91, 724-32		14
437	Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). <i>Diabetes Care</i> , 2013 , 36, 2945-51	14.6	193
436	Incretin hormones and the satiation signal. 2013 , 37, 1161-8		114
435	Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). <i>Diabetes Care</i> , 2013 , 36, 2543-50	14.6	129
434	Practical Use of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Primary Care. 2013 , 31, 148-157		32
433	Evolution of Exenatide as a Diabetes Therapeutic. 2013 , 9, 161-193		2
432	Obesity pharmacotherapy: current perspectives and future directions. 2013 , 9, 33-54		12
431	Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus. 2013 , 28, 262-74		35
430	Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. 2013 , 9, 155-63		119

429	Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. 2013 , 6, 31-41	24
428	Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries. 2013 , 6, 171-85	6
427	Improved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2r ^{0/0} mice treated with alogliptin. 2013 , 6, 493-9	14
426	Exendin-4 protects mitochondria from reactive oxygen species induced apoptosis in pancreatic Beta cells. 2013 , 8, e76172	14
425	Evolution of exenatide as a diabetes therapeutic. 2013 , 9, 161-93	45
424	Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. 2014 , 7, 107-20	18
423	Therapeutic Approaches for Preserving or Restoring Pancreatic β Cell Function and Mass. 2014 , 38, 426-36	22
422	Treating the elderly diabetic patient: special considerations. 2014 , 7, 391-400	6
421	Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes. 2014 , 3, 595-613	7
420	Systematic Review and Network Meta-analysis to Compare Dapagliflozin with other Diabetes Medications in Combination with Metformin for Adults with Type 2 Diabetes. 2014 , 01,	
419	Assessment of pancreatic β cell function: review of methods and clinical applications. 2014 , 10, 2-42	119
418	Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes. 2014 , 10, 661-4	12
417	Type 2 Diabetes Treatment Recommendations Update: Appropriate Use of Dipeptidyl Peptidase-4 Inhibitors. 2014 , 05,	1
416	Exendin-4 effects on islet volume and number in the mouse pancreas. 2014 , 115, 502-7	0
415	Adverse Effects of GLP-1 Receptor Agonists. 2014 , 11, 202-30	119
414	The anorexic effect of Ex4/Fc through GLP-1 receptor activation in high-fat diet fed mice. 2014 , 46, 675-81	3
413	Clinical and laboratory characteristics of exenatide-given patients in endocrinology clinic of a university hospital. 2014 , 41, 128-132	1
412	Clinical pharmacology of albiglutide, a GLP-1 receptor agonist. 2014 , 126, 84-97	23

411	Application of clinical judgment and guidelines to achieving glycemic goals in type 2 diabetes: focus on pharmacologic therapy. 2014 , 126, 95-106		7
410	Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes (Teil 2). 2014 , 9, 241-299		1
409	Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry. 2014 , 24, 1346-53		34
408	Efficacy and tolerability of GLP-1 agonists in patients with type 2 diabetes mellitus: an Indian perspective. 2014 , 5, 159-65		4
407	Long-term tolerance and efficacy of adjunctive exenatide therapy on glycaemic control and bodyweight in type 2 diabetes: a retrospective study from a specialist diabetes outpatient clinic. 2014 , 44, 345-53		3
406	Early therapy for type 2 diabetes in China. 2014 , 2, 992-1002		42
405	Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). 2014 , 31, 176-84		93
404	The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. 2014 , 16, 673-88		76
403	Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. 2014 , 16, 900-9		112
402	Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers. 2014 , 106, 567-75		21
401	Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes. 2014 , 30, 521-9		110
400	Modulation of the pancreatic islet-stress axis as a novel potential therapeutic target in diabetes mellitus. 2014 , 95, 195-222		6
399	Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. <i>Diabetes Care</i> , 2014 , 37, 2763-73	14.6	182
398	Synthesis of evidence for reimbursement decisions: a Bayesian reanalysis. 2014 , 30, 438-45		
397	Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists. 2014 , 32, 32-43		5
396	Evidence-based practice use of incretin-based therapy in the natural history of diabetes. 2014 , 126, 66-84		9
395	Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes. 2014 , 9, 659-670		12
394	Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes. 2014 , 126, 60-72		20

393	Geniposide and its iridoid analogs exhibit antinociception by acting at the spinal GLP-1 receptors. 2014 , 84, 31-45	52
392	A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment. 2014 , 16, 170-8	6
391	The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. 2014 , 16, 9-21	87
390	Use of exenatide and liraglutide in Denmark: a drug utilization study. 2014 , 70, 205-14	9
389	New developments in diabetes management: medications of the 21st century. 2014 , 36, 477-84	22
388	Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption. 2014 , 231, 3729-44	6
387	Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus. 2014 , 74, 325-51	37
386	Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach. 2014 , 5, 333-40	6
385	Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes. 2014 , 31, 289-317	7
384	System-based approaches to decode the molecular links in Parkinson's disease and diabetes. 2014 , 72 Pt A, 84-91	66
383	Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration. 2014 , 30, 1209-18	7
382	Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. 2014 , 27, 130-9	94
381	Tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obese, Korean patients with type 2 diabetes. 2014 , 5, 554-62	14
380	Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials. 2014 , 31, 861-72	14
379	Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum. <i>Diabetes Care</i> , 2014 , 37, 2647-59	14.6 48
378	Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose. 2014 , 34, 237-60	59
377	GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. 2014 , 63, 4186-96	198
376	[Effects of GLP-1 receptor agonists on carbohydrate metabolism control]. 2014 , 143 Suppl 2, 18-22	

375	[Twice-daily and weekly exenatide: Clinical profile of two pioneer formulations in incretin therapy]. 2014 , 143 Suppl 2, 23-7		
374	Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). <i>Diabetes Care</i> , 2014 , 37, 2159-67	14.6	243
373	What are the pharmacotherapy options for treating prediabetes?. 2014 , 15, 2003-18		20
372	Initial evidence that GLP-1 receptor blockade fails to suppress postprandial satiety or promote food intake in humans. 2014 , 82, 85-90		12
371	The gut-brain axis in obesity. 2014 , 28, 559-71		45
370	Incretins: their physiology and application in the treatment of diabetes mellitus. 2014 , 30, 354-71		63
369	Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. 2014 , 384, 1349-57		318
368	[Safety and tolerability of GLP-1 receptor agonists]. 2014 , 143 Suppl 2, 35-40		1
367	GLP-1R activation for the treatment of stroke: updating and future perspectives. 2014 , 15, 233-42		17
366	Effects of GLP-1 on appetite and weight. 2014 , 15, 181-7		106
365	Extra-pancreatic effects of incretin-based therapies. 2014 , 47, 360-71		26
364	Gastrointestinal hormones and polycystic ovary syndrome. 2014 , 47, 668-78		7
363	Quantifying energy intake changes during obesity pharmacotherapy. 2014 , 22, 2105-8		11
362	Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. 2014 , 221, T1-16		141
361	A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. 2014 , 22, 403-10		16
360	The role of incretin-based therapies in prediabetes: a review. 2014 , 8, 286-94		7
359	Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. 2014 , 25, 407-14		101
358	Glucagon-like peptide-1 receptor agonists for diabetes mellitus: a role in cardiovascular disease. 2014 , 129, 2305-12		30

357	New treatments for type 2 diabetes: cardiovascular protection beyond glucose lowering?. 2014 , 23, 997-1008	8
356	Permeability of exendin-4-loaded chitosan nanoparticles across MDCK cell monolayers and rat small intestine. 2014 , 37, 740-7	12
355	Diabetes and Health Care. 2014 , 1-129	1
354	Implications of incretin-based therapies on cardiovascular disease. 2015 , 69, 531-49	10
353	American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan 2015. 2015 , 21, 1-87	390
352	Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans. 2015 , 17, 878-86	65
351	Characterization of Patients with Type 2 Diabetes according to Body Mass Index: Korea National Health and Nutrition Examination Survey from 2007 to 2011. 2015 , 30, 514-21	13
350	The role of hormonal treatment in type 2 diabetes mellitus. 2015 , 31	
349	A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. 2015 , 4, 212283	198
348	GLP-1 based therapeutics: simultaneously combating T2DM and obesity. 2015 , 9, 92	67
347	The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis. 2015 , 10, e0126769	102
346	Incretin System in the Pathogenesis of Type 2 Diabetes and the Role of Incretin Based Therapies in the Management of Type 2 Diabetes. 2015 ,	1
345	Determining predictors of early response to exenatide in patients with type 2 diabetes mellitus. 2015 , 2015, 162718	19
344	New pharmacological approaches to diabetes management. 2015 , 26, 140-146	1
343	Treatment of prediabetes. 2015 , 6, 1207-22	42
342	Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. 2015 , 36, 2288-96	178
341	Diabetes: A New Horizon and Approach to Management. 2015 , 29-44	3
340	3 Medical Management of Obesity. 2015 , 15-38	

339	Liraglutide and obesity: a review of the data so far. 2015 , 9, 1867-75	63
338	Clinical results of islet transplantation. 2015 , 98, 86-91	21
337	Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes. 2015 , 10, 11-21	18
336	A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes. 2015 , 31, 125-35	8
335	Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. 2015 , 6, 3-18	33
334	Chronic elevation of systemic glucagon-like peptide-1 following surgical weight loss: association with nausea and vomiting and effects on adipokines. 2015 , 25, 386-91	6
333	Metabolic vs. hedonic obesity: a conceptual distinction and its clinical implications. 2015 , 16, 234-47	53
332	Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study. 2015 , 52, 727-32	47
331	Potential side effects to GLP-1 agonists: understanding their safety and tolerability. 2015 , 14, 207-18	28
330	The gut sensor as regulator of body weight. 2015 , 49, 35-50	22
329	Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial. 2015 , 90, 356-65	45
328	Liraglutide for Type 2 diabetes and obesity: a 2015 update. 2015 , 13, 753-67	41
327	Effects of three injectable antidiabetic agents on glycaemic control, weight change and drop-out in type 2 diabetes suboptimally controlled with metformin and/or a sulfonylurea: A network meta-analysis. 2015 , 109, 451-60	12
326	Stimulation of GLP-1 secretion downstream of the ligand-gated ion channel TRPA1. 2015 , 64, 1202-10	39
325	ANTI-OBESITY PHARMACOTHERAPY AND THE POTENTIAL FOR PREVENTING PROGRESSION FROM PREDIABETES TO TYPE 2 DIABETES. 2015 , 21, 634-44	6
324	Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (<i>Macaca mulatta</i>) brain. 2015 , 156, 255-67	103
323	Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin. 2015 , 6, 61-74	19
322	Pharmacologic treatment of type 2 diabetes: injectable medications. 2015 , 49, 700-14	19

321	Cardiometabolic Effects of a New Class of Antidiabetic Agents. 2015 , 37, 1178-94	30
320	Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis. 2015 , 10, e0125879	98
319	Combination therapy in type 2 diabetes mellitus. 2015 , 686-708	1
318	Incretin-based therapies. 2015 , 726-744	
317	Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials. 2015 , 48, 107-15	118
316	Human Studies as a Source of Target Information. 2015 , 107-113	
315	GLP-1-Exendin-4/IgG4 (Fc) fusion protein as a novel drug for diabetes treatment. 2015 , 123, 371-5	8
314	Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy. 2015 , 127, 827-41	10
313	Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers. 2015 , 32, 650-61	1
312	The non-peptide GLP-1 receptor agonist WB4-24 blocks inflammatory nociception by stimulating δ -endorphin release from spinal microglia. 2015 , 172, 64-79	47
311	Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , 2015 , 38, 1567-82	14.6 133
310	Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice. 2015 , 81, 459-467	69
309	GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice. 2015 , 41, 32S-46S	8
308	Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists. 2015 , 6, 239-56	64
307	Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective. 2015 , 17, 335-42	9
306	Incretin-based therapies. 2015 , 99, 107-29	22
305	Pharmacological Management of the Obese Patient. 2015 , 9, 137-156	
304	Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding. 2016 , 6, 243-53	44

303	Exenatide. 2016 , 214-219	
302	The Hypoglycemic Effect of Intravenous Laser Therapy in Diabetic Mellitus Type 2 Patients; A Systematic Review and Meta-analyses. 2016 , 01,	2
301	Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women. 2016 , 2016, 1309502	5
300	Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients. 2016 , 2016, 6962574	5
299	The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review. 2016 , 13,	2
298	Update on the treatment of type 2 diabetes mellitus. 2016 , 7, 354-95	269
297	The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis. 2016 , 82, 301-14	19
296	How to Use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies. 2016 , 471-492	
295	Non-Insulin Parenteral Therapies. 2016 , 455-470	
294	Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program. 2016 , 16, 44	11
293	Exendin-4 protects bone marrow-derived mesenchymal stem cells against oxygen/glucose and serum deprivation-induced apoptosis through the activation of the cAMP/PKA signaling pathway and the attenuation of ER stress. 2016 , 37, 889-900	27
292	Exenatide loaded PLGA microspheres for long-acting antidiabetic therapy: preparation, characterization, pharmacokinetics and pharmacodynamics. 2016 , 6, 37452-37462	16
291	One hundred top-cited articles in endocrinology and metabolism: a bibliometric analysis. 2016 , 54, 564-571	6
290	The peptide agonist-binding site of the glucagon-like peptide-1 (GLP-1) receptor based on site-directed mutagenesis and knowledge-based modelling. 2015 , 36, e00285	23
289	Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon. 2016 , 326, 279-341	11
288	Standards of care for type 2 diabetes in China. 2016 , 32, 442-58	185
287	Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials. 2016 , 70, 649-56	9
286	Once-daily liraglutide (1.2 mg) compared with twice-daily exenatide (10 µg) in the treatment of type 2 diabetes patients: An indirect treatment comparison meta-analysis. 2016 , 8, 866-876	4

285	Cost-effectiveness of a risk-based secondary screening programme of type 2 diabetes. 2016 , 32, 710-729	5
284	New Approaches to Feline Diabetes Mellitus: Glucagon-like peptide-1 analogs. 2016 , 18, 733-43	6
283	Targeting the gastrointestinal tract to treat type 2 diabetes. 2016 , 230, R95-R113	18
282	An intrinsic agonist mechanism for activation of glucagon-like peptide-1 receptor by its extracellular domain. 2016 , 2, 16042	23
281	Role of glucagon-like peptide 1 receptor agonists in management of obesity. 2016 , 73, 1493-507	30
280	A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. 2016 , 8, 341ra76	77
279	Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release. 2016 , 6, 36222	56
278	Dulaglutid: GLP-1-Rezeptoragonist zur einmal wahentlichen Therapie des Typ-2-Diabetes. 2016 , 11, 398-417	1
277	Efficacy of hypoglycemic treatment in type 2 diabetes stratified by age or diagnosed age: a meta-analysis. 2016 , 17, 1591-8	2
276	Histoire des incretines : Du chien brun au monstre de Gila. 2016 , 10, 285-290	0
275	Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. 2016 , 12, 566-92	205
274	Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial. 2016 , 17, 160	5
273	Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes. 2016 , 18, 834-9	10
272	Cardiovascular safety of anti-diabetic drugs. 2016 , 2, 32-43	34
271	Gender-related different effects of a combined therapy of Exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus. 2016 , 30, 686-92	18
270	A systematic review of the safety of incretin-based therapies in type 2 diabetes. 2016 , 11, 217-232	4
269	A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus. 2016 , 7, 27-43	33
268	Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis. 2016 , 114, 160-72	11

267	GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1. 2016 , 59, 1059-69	64
266	The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. 2016 , 7, 92-107	27
265	Hindbrain GLP-1 receptor mediation of cisplatin-induced anorexia and nausea. 2016 , 153, 109-14	16
264	Adherence to NICE guidance on glucagon-like peptide-1 receptor agonists among patients with type 2 diabetes mellitus: an evaluation using the Clinical Practice Research Datalink. 2016 , 32, 49-60	7
263	Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review. 2016 , 9, 241-65	16
262	The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide. 2016 , 32, 61-76	20
261	Role of gastrointestinal hormones in feeding behavior and obesity treatment. 2016 , 51, 93-103	16
260	Type 2 Diabetes. 2016 ,	2
259	Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome. 2017 , 12, 221-228	35
258	Polyethylene glycol loxanatide injections added to metformin effectively improve glycemic control and exhibit favorable safety in type 2 diabetic patients. 2017 , 9, 158-167	14
257	Exenatide: pharmacokinetics, clinical use, and future directions. 2017 , 18, 555-571	39
256	The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy. 2017 , 34, 638-657	3
255	Glucagon-like peptide-1 agonists for weight loss in people with obesity. 2017 , 5, 29-43	
254	Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?. 2017 , 19, 25	1
253	VMP1-related autophagy induced by a fructose-rich diet in <i>β</i> cells: its prevention by incretins. 2017 , 131, 673-687	5
252	The effects of GLP-1 analogues on pre-diabetes of the children. 2017 , 13, 1426-1430	5
251	Long-Acting Release Formulation of Exendin-4 Based on Biomimetic Mineralization for Type 2 Diabetes Therapy. 2017 , 11, 5062-5069	37
250	Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists. 2017 , 39, 1244-1264	9

249	Effect of continuous exenatide infusion on cardiac function and peri-operative glucose control in patients undergoing cardiac surgery: A single-blind, randomized controlled trial. 2017 , 19, 1818-1822	14
248	Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates. 2017 , 33, 1155-1163	4
247	WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes. 2017 ,	1
246	Population Pharmacokinetics of an Extended-Release Formulation of Exenatide Following Single- and Multiple-Dose Administration. 2017 , 19, 487-496	11
245	Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. 2017 , 19, 524-536	216
244	Proportional Feedback Control of Energy Intake During Obesity Pharmacotherapy. 2017 , 25, 2088-2091	13
243	Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes. 2017 , 41, 524-535	40
242	Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c $\geq 10.0\%$: Two pooled analyses including 20 randomised controlled trials. 2017 , 71, e13029	3
241	A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus. 2017 , 14, 3279-3287	6
240	Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus. 2017 , 37, 1107-1115	2
239	The Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Type 2 Diabetes. 2017 , 5, 79-89	6
238	Efficacy and Safety of GLP-1 Receptor Agonists Across the Spectrum of Type 2 Diabetes Mellitus. 2017 , 125, 419-435	6
237	Microneedle-array patches loaded with dual mineralized protein/peptide particles for type 2 diabetes therapy. 2017 , 8, 1777	91
236	Thioamide Substitution Selectively Modulates Proteolysis and Receptor Activity of Therapeutic Peptide Hormones. 2017 , 139, 16688-16695	43
235	Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide to Characterize Its Antiobesity Effects in Diet-Induced Obese Mice. 2017 , 362, 441-449	5
234	GLP-1 receptor signalling promotes β cell glucose metabolism via mTOR-dependent HIF-1 β activation. 2017 , 7, 2661	46
233	Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. 2017 , 19, 336-347	120
232	Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146. 2017 , 281, 25-40	20

231	Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes. 2017 , 19, 200-207	23
230	Population pharmacokinetics of exenatide. 2017 , 83, 517-526	13
229	Cardiovascular safety of therapies for type 2 diabetes. 2017 , 16, 13-25	5
228	Novel GLP-1 Analog Supaglutide Reduces HFD-Induced Obesity Associated with Increased Ucp-1 in White Adipose Tissue in Mice. 2017 , 8, 294	12
227	Input Estimation for Extended-Release Formulations Exemplified with Exenatide. 2017 , 5, 24	2
226	Bioactivity of a modified human Glucagon-like peptide-1. 2017 , 12, e0171601	3
225	Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice. 2017 , 17, 68	4
224	Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. 2017 , 22, 15-26	26
223	Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials. 2017 , 10, 111-122	19
222	Hypoglycemia: a review of definitions used in clinical trials evaluating antihyperglycemic drugs for diabetes. 2017 , 9, 291-296	27
221	Phase III Study on Efficacy and Safety of Triple Combination (Exenatide/Metformin/Biphasic Insulin Aspart) Therapy for Type 2 Diabetes Mellitus. 2018 , 25, e609-e616	1
220	A novel peptide Phylloseptin-PBu from <i>Phyllomedusa burmeisteri</i> possesses insulinotropic activity via potassium channel and GLP-1 receptor signalling. 2018 , 22, 2804-2814	3
219	A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs. 2018 , 9, 1149-1167	25
218	Japanese Clinical Practice Guideline for Diabetes 2016. 2018 , 9, 657	136
217	Real-world clinical responses in patients with type 2 diabetes mellitus adding exenatide BID (EBID) or mealtime insulin to basal insulin: a retrospective study using electronic medical record data. 2018 , 34, 1045-1051	1
216	A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials. 2018 , 20 Suppl 1, 22-33	118
215	Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice. 2018 , 64, 33-43	37
214	Exenatide treatment causes suppression of serum fasting ghrelin levels in patients with type 2 diabetes mellitus. 2018 , 7, 193-198	2

213	Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes. 2018 , 14, 207-217	6
212	A vitamin B12 conjugate of exendin-4 improves glucose tolerance without associated nausea or hypophagia in rodents. 2018 , 20, 1223-1234	18
211	Discovery and structure-activity relationships study of thieno[2,3-b]pyridine analogues as hepatic gluconeogenesis inhibitors. 2018 , 152, 307-317	20
210	Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial. 2018 , 85, 116-125	15
209	Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin. 2018 , 20, 638-645	4
208	Pharmacotherapy of type 2 diabetes: An update. 2018 , 78, 13-42	103
207	Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database. 2018 , 20, 831-839	11
206	A Novel Peptide with Similar Pharmacology to Exenatide in Rodents as GLP-1 Receptor Agonist. 2018 , 24, 271-278	
205	Penetration of new antidiabetic medications in East Asian countries and the United States: A cross-national comparative study. 2018 , 13, e0208796	6
204	Uncoupling proteins as a therapeutic target to protect the diabetic heart. 2018 , 137, 11-24	15
203	Satiating effect of a sodium caseinate hydrolysate and its fate in the upper gastrointestinal tract. 2018 , 49, 306-313	3
202	GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes. 2018 , 2018, 4020492	51
201	Japanese Clinical Practice Guideline for Diabetes 2016. 2018 , 9, 1-45	114
200	Oxidative Stress, Intrauterine Growth Restriction, and Developmental Programming of Type 2 Diabetes. 2018 , 33, 348-359	29
199	Clinical pharmacology of glucagon-like peptide-1 receptor agonists. 2018 , 17, 333-350	26
198	The Effect of Diabetes-Specific Enteral Nutrition Formula on Cardiometabolic Parameters in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. 2019 , 11,	13
197	Sustained release and pharmacologic evaluation of human glucagon-like peptide-1 and liraglutide from polymeric microparticles. 2019 , 36, 747-758	7
196	Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis. 2019 , 10, 2183-2199	16

195	Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes: A Network Meta-analysis. 2019,	
194	Dietary Intake and Type 2 Diabetes. 2019, 11,	12
193	Glucagon-like peptide 1 (GLP-1). 2019, 30, 72-130	364
192	Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials. 2019, 10, 1249-1270	1
191	Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes. 2019, 8,	12
190	Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output. 2019, 41, 73-84	22
189	Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies. 2019, 198, 160-188	39
188	Diabetic Pharmacotherapies in Kidney Disease. 2019, 49-74	
187	GLP-1 Limits Adipocyte Inflammation and Its Low Circulating Pre-Operative Concentrations Predict Worse Type 2 Diabetes Remission after Bariatric Surgery in Obese Patients. 2019, 8,	7
186	Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity. 2019, 2019, 1365162	14
185	Gut Peptide Agonism in the Treatment of Obesity and Diabetes. 2019, 10, 99-124	1
184	The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. 2019, 2019, 8083417	0
183	Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes. 2019, 20,	25
182	Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?. 2019, 35, e3070	104
181	Exendin-4 overcomes cytokine-induced decreases in gap junction coupling via protein kinase A and Epac2 in mouse and human islets. 2019, 597, 431-447	11
180	Multivalent activation of GLP-1 and sulfonylurea receptors modulates β cell second-messenger signaling and insulin secretion. 2019, 316, C48-C56	4
179	Modeling the impact of preplanned dose titration on delayed response. 2019, 29, 287-305	1
178	Effect of baseline body mass index on glycemic control and weight change with exenatide monotherapy in Chinese drug-naïve type 2 diabetic patients. 2019, 11, 509-518	8

177	Anti-diabetic drugs recent approaches and advancements. 2020 , 28, 115263		48
176	Novel glucagon- and OXM-based peptides acting through glucagon and GLP-1 receptors with body weight reduction and anti-diabetic properties. 2020 , 95, 103538		5
175	Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta-analysis. 2020 , 3, e00100		2
174	The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship. 2020 , 103, 154031		3
173	AMPK in the Ventromedial Nucleus of the Hypothalamus: A Key Regulator for Thermogenesis. 2020 , 11, 578830		3
172	Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Diabetes Care</i> , 2020 , 43, 1948-1957	14.6	21
171	Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis. 2020 , 31, 107768		9
170	Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. 2020 , 18, 322		1
169	Japanese Clinical Practice Guideline for Diabetes 2019. 2020 , 11, 1020-1076		46
168	Japanese Clinical Practice Guideline for Diabetes 2019. 2020 , 11, 165-223		75
167	Comparison of Blood Glucose Variability Between Exenatide and Biphasic Insulin Aspart 30 in Chinese Participants with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Multicenter, Open-Label, Randomized Trial. 2020 , 11, 2313-2328		1
166	SYSTEMATIC REVIEW ON MEDICAMENTS USED IN MANAGEMENT OF DIABETES MELLITUS. 2020 , 21-29		
165	Hydrocarbon-Stitched Peptide Agonists of Glucagon-Like Peptide-1 Receptor. 2020 , 15, 1340-1348		5
164	Weight-centric pharmacological management of type 2 diabetes mellitus - An essential component of cardiovascular disease prevention. 2020 , 34, 107619		7
163	A second-generation glucagon-like peptide-1 receptor agonist mitigates vomiting and anorexia while retaining glucoregulatory potency in lean diabetic and emetic mammalian models. 2020 , 22, 1729-1741		6
162	Microwell-based pancreas-on-chip model enhances genes expression and functionality of rat islets of Langerhans. 2020 , 514, 110892		11
161	Assessment of Second-Generation Diabetes Medication Initiation Among Medicare Enrollees From 2007 to 2015. 2020 , 3, e205411		3
160	GLP-1 Analogues as a Complementary Therapy in Patients after Metabolic Surgery: a Systematic Review and Qualitative Synthesis. 2020 , 30, 3561-3569		1

159	Acupuncture for patients with glucagon-like peptide-1 receptor agonists-induced nausea and vomiting: A systematic review protocol. 2020 , 99, e20343	
158	Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial. 2020 , 57, 991-1000	2
157	Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial. 2020 , 8, 313-324	18
156	Discovery and pharmacology of the covalent GLP-1 receptor (GLP-1R) allosteric modulator BETP: A novel tool to probe GLP-1R pharmacology. 2020 , 88, 173-191	7
155	Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. 2021 , 1307, 171-192	11
154	Safety, Tolerability and Pharmacokinetics of Single Dose Polyethylene Glycolated Exenatide Injection (PB-119) in Healthy Volunteers. 2020 , 45, 361-369	3
153	Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists. 2020 , 37, 100991	16
152	An overview of GLP-1 agonists and recent cardiovascular outcomes trials. 2020 , 96, 156-161	52
151	Insulin and leptin as potential cognitive enhancers in metabolic disorders and Alzheimer's disease. 2020 , 171, 108115	9
150	Non-targeted metabolomic analysis predicts the therapeutic effects of exenatide on endothelial injury in patients with type 2 diabetes. 2021 , 35, 107797	1
149	Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients. 2021 , 55, 496-508	9
148	Liraglutide and Dulaglutide Have Comparable HbA1c Reduction in Emirati Patients with T2DM. 2021 , 11, 103-117	
147	Exendin-4 inhibits the survival and invasiveness of two colorectal cancer cell lines via suppressing GS3K/β-catenin/NF-κB axis through activating SIRT1. 2021 , 45, 1337-1353	0
146	Pathogenesis, Diagnosis, and Management of Metabolic Syndrome: A Comprehensive Review. 2021 , 4, 39-45	0
145	Symptomatic Hypoglycemia After Gastric Bypass: Incidence and Predictive Factors in a Cohort of 1,138 Consecutive Patients. 2021 , 29, 681-688	1
144	Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study. 2021 , 64, 1066-1078	0
143	Synthesis, Optimization, and Biological Evaluation of Corrinated Conjugates of the GLP-1R Agonist Exendin-4. 2021 , 64, 3479-3492	1
142	The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability. 2021 , 38, 355-373	2

141	Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder. 2021 , 221, 108614	8
140	A Bibliometrics Analysis of Metformin Development From 1980 to 2019. 2021 , 12, 645810	3
139	Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. 2021 , 22,	9
138	The Role of GIP in the Regulation of GLP-1 Satiety and Nausea. 2021 , 70, 1956-1961	5
137	A pH-Triggered Self-Unpacking Capsule Containing Zwitterionic Hydrogel-Coated MOF Nanoparticles for Efficient Oral Exendin-4 Delivery. 2021 , 33, e2102044	12
136	Prediabetes: how pathophysiology drives potential intervention on a subclinical disease with feared clinical consequences. 2021 , 46, 272-292	0
135	Potential Therapeutic Applications of Synthetic Conotoxin s-cal14.2b, Derived from , for Treating Type 2 Diabetes. 2021 , 9,	2
134	Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin. 2021 , 27, 790-797	0
133	DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity. 2021 , 278, 119574	2
132	Anti-diabetic drugs and weight loss in patients with type 2 diabetes. 2021 , 171, 105782	9
131	Xenin and Related Peptides: Potential Therapeutic Role in Diabetes and Related Metabolic Disorders. 2021 , 14, 11795514211043868	
130	The Role of Incretins in Insulin Secretion. 2010 , 57-74	1
129	Neuroendocrine Control of Food Intake. 2006 , 1-21	1
128	Metformin [From Devil to Angel. 2007 , 77-86	3
127	The Transition from Oral Agents to Combination Insulin/Oral Therapy. 2008 , 169-181	3
126	Environmental Inputs, Intake of Nutrients, and Endogenous Molecules Contributing to the Regulation of Energy Homeostasis. 2009 , 41-75	1
125	GLP-1 agonists and dipeptidyl-peptidase IV inhibitors. 2011 , 53-74	26
124	Incretins and Regulation of Insulin Secretion. 2008 , 335-378	4

123	Diabetes Mellitus. 2008 , 4385-4399	0
122	DIABETES MELLITUS. 2009 , 557-570	1
121	Mechanisms of action for the anti-obesogenic activities of phytochemicals. 2020 , 180, 112513	3
120	Glycemic Management. 2007 , 13, 16-34	3
119	Lamiophlomis rotata, an orally available Tibetan herbal painkiller, specifically reduces pain hypersensitivity states through the activation of spinal glucagon-like peptide-1 receptors. 2014 , 121, 835-51	42
118	Vertical sleeve gastrectomy lowers kidney SGLT2 expression in the mouse.	2
117	Bowels control brain: gut hormones and obesity. 2012 , 22, 283-97	16
116	The role of gut hormones in glucose homeostasis. 2007 , 117, 24-32	436
115	Beta cell transplantation and immunosuppression: can't live with it, can't live without it. 2007 , 117, 2380-2	6
114	Exenatide and the treatment of patients with Parkinson's disease. 2013 , 123, 2730-6	268
113	Neonatal exendin-4 reduces growth, fat deposition and glucose tolerance during treatment in the intrauterine growth-restricted lamb. 2013 , 8, e56553	13
112	Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids. 2013 , 8, e78154	29
111	Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. 2016 , 11, e0154206	18
110	Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity. 2018 , 15, 22-30	4
109	Exendin-4 effects on islet volume and number in mouse pancreas. 2013 , 49, 745-752	1
108	Encapsulated cell grafts to treat cellular deficiencies and dysfunction. 2011 , 39, 473-91	40
107	Second steps in managing type 2 diabetes. 2018 , 41, 141-144	2
106	New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. 2005 , 2, 61-9	29

105	Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. 2008 , 5, 73-94	82
104	Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists. 2009 , 6, 247-59	13
103	Incretin therapy--present and future. 2011 , 8, 307-22	21
102	The role of incretin therapy at different stages of diabetes. 2011 , 8, 323-38	20
101	A review of exenatide as adjunctive therapy in patients with type 2 diabetes. 2009 , 3, 219-40	31
100	Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies. 2010 , 3, 227-42	8
99	Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes. 2009 , 2, 135-44	2
98	Emerging role of GLP-1 receptor agonists in the treatment of obesity. 2010 , 3, 263-73	8
97	Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus. 2010 , 3, 165-72	3
96	Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes. 2006 , 2, 69-77	23
95	Current Options for the Pharmacotherapy of Obesity. 2019 , 25, 2019-2032	2
94	GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus. 2020 , 16, 279-292	3
93	Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes. 2019 , 57, 233-240	12
92	Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease. 2014 , 20, 7356-65	30
91	No Superiority of Exenatide over Insulin in Diabetic Patients in Terms of Weight Reduction or Incidence of Adverse Effects: A Meta-analysis. 2011 , 7, 749-756	8
90	Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future. 2016 , 20, 254-67	44
89	Pleiotropic effects of incretins. 2012 , 16 Suppl 1, S47-56	24
88	Safety and Efficacy of Exenatide in Combination with Insulin in Patients with Type 2 Diabetes Mellitus. 2008 , 14, 285-292	10

87	Exenatide efficacy in unselected patients: Comparison with clinical trials. 2012 , 02, 118-121	2
86	Sulfonylurea Glimepiride: A Proven Cost Effective, Safe and Reliable War Horse in Combating Hyperglycemia in Type 2 Diabetes. 2015 , 05, 211-226	7
85	Pleiotropic Effects of GLP-1. Cardiovascular Evidence of Effectiveness. 2013 , 04, 647-650	2
84	Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndrome. 2016 , 7, 441-448	15
83	Type 2 diabetes in children and adolescents: a review for the primary care provider. 2006 , 35, 880-7	1
82	Pharmacological Treatment of the Overweight Patient. 2007 , 203-256	1
81	The Incretin Modulators [Incretin Mimetics (GLP-1 Receptor Agonists) and Incretin Enhancers (DPP-4 Inhibitors)]. 2007 , 111-141	
80	Sovremennye vozmozhnosti farmakoterapii sakharnogo diabeta 2 tipa pri pomoshchi analogov glyukagonopodobnogo peptida-1 (GPP-1). 2007 , 10, 9-15	1
79	Incretin Enhancers, Incretinomimetics [From Therapeutic Concept to Clinical Application. 2007 , 1, 133-146	
78	Treatment Strategies for Type 2 Diabetes Based on Incretin Action. 2007 , 159-169	1
77	Combination Therapy for Treatment of Type 2 Diabetes. 2007 , 207-226	
76	Type 2 Diabetes Mellitus: An Evidence-Based Approach to Practical Management. 2008 , 151-167	
75	Neue Arzneimittel 2007. 2008 , 47-118	
74	Exenatid. 2008 , 29,	
73	The Effects of Exendin-4 on IRS-2 Expression and Phosphorylation in INS-1 Cells. 2008 , 32, 102	
72	Type 2 Diabetes and Concomitant Illness. 2008 , 203-233	
71	Vybor taktiki lecheniya u patsientov s neudovletvoritel'noy kompensatsiey sakharnogo diabeta 2 tipa: vozmozhnosti naznacheniya mimetika inkretinov eksenatida (na primere klinicheskogo sluchaya). 2008 , 11, 84-88	
70	Non-insulin agents in the management of type 2 diabetes. 2009 , 19-30	

69 INSULINS AND OTHER HYPOGLYCEMIC DRUGS. **2009**, 357-473

68 Glucagon and the Glucagon-Like Peptides. **2010**, 660-672

67 Obesity. **2010**, 555-565

66 Obesity. **2010**, 99-114.e4

65 How to use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies. 494-513

64 The Gut, Brain, and Peripheral Tissue Connection: Metabolic Disease in the Incretin Era. **2010**, 16, 33-38

63 Principles of Obesity Therapy. **2011**, 359-379

62 Pharmacologic Approaches to Type 2 Diabetes and Obesity in Children and Adolescents. **2011**, 275-310

61 References. **2011**, 283-360

60 Glucagon-like peptide-1 alleviating peripheral neuropathy in diabetic patients: advance in mechanism. **2011**, 31, 329-333

59 [Incretin-based therapy for treating patients with type 2 diabetes]. **2011**, 152, 1931-40

1

58 Efficacy of GLP-1 analog to achieve metabolic control and correction of body weight in patients with type 2 diabetes mellitus. **2011**, 10, 114-119

57 References, Bibliography & Further Reading. **2012**, 287-306

56 Food Intake and Gut Hormones. **2013**, 22, 197

55 The collateral benefits of noninsulin therapies for Type 2 diabetes. **2013**, 3, 145-160

54 The new therapeutic modalities for the treatment of type 2 diabetes mellitus: insulin detemir added to liraglutide. **2013**, 59, 50-55

1

53 Medikamentöse Therapie der Adipositas. **2015**, 535-542

52 Exenatide Effects on Cardiometabolic Risk and Weight in Adolescents with Morbid Obesity and Type 2 Diabetes Mellitus: Two Case Reports. **2015**, 1,

1

- 51 Treating Type 2 Diabetes Mellitus. **2016**, 1-24
- 50 New Oral Diabetes Drugs are more effective than Older Agents: Real or a Fraud?. **2016**, 3,
- 49 Treating Type 2 Diabetes Mellitus. **2017**, 905-927
- 48 Treating Type 2 Diabetes Mellitus. **2017**, 1-24
- 47 Marked Improvement in Glycemic Control with Exenatide on Addition to Metformin, Sulfonylurea and Insulin Glargine in Type 2 Diabetes Mellitus, a Real World Experience. **2018**, 08, 152-159
- 46 Glucagon like peptide 1 receptor agonists: a therapy for diabetes management. **2018**, 32, 23-30
- 45 Sustained release and pharmacologic effects of human glucagon-like peptide-1 and liraglutide from polymeric microparticles. o
- 44 Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity.. **2018**, 96, 746-753
- 43 Choosing Medications for Weight Loss in Type 2 Diabetes Mellitus. **2021**, 187-197
- 42 Incretin-Based Therapy for the Management of Type 2 Diabetes. **2021**, 146-160
- 41 Why drugs?. **2008**, 1-10
- 40 Introduction to Diabetes. **2006**, 1-37
- 39 Diabetes Mellitus, Hyperinsulinemia, and Coronary Artery Disease. **2006**, 113-143
- 38 Weight Loss Medications and the Metabolic Syndrome. **2008**, 301-322
- 37 Coming of Age for the Incretins. **2008**, 269-290
- 36 The burden of type 2 diabetes: strategies to prevent or delay onset. **2007**, 3, 511-20 13
- 35 Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. **2008**, 10, 171 34
- 34 Role and development of GLP-1 receptor agonists in the management of diabetes. **2009**, 2, 37 2

33	Incretin agents in type 2 diabetes. 2010 , 56, 639-48	30
32	Tackling obesity: new therapeutic agents for assisted weight loss. 2010 , 3, 95-112	3
31	Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review. 2010 , 3, 155-63	10
30	Alogliptin: a new addition to the class of DPP-4 inhibitors. 2009 , 2, 117-26	15
29	Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. 2011 , 5, e35-48	50
28	Diabetes: glycaemic control in type 2 (drug treatments). 2012 , 2012,	6
27	Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering. 2012 , 16, 100-5	3
26	Evaluation and management of diabetes mellitus. 2008 , 1, 39-48	2
25	Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications. 2006 , 4, 129-33	3
24	Exenatide's effect in reducing weight and glycosylated hemoglobin level in an Arab population with type 2 diabetes. 2014 , 35, 1404-7	
23	Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes. 2017 , 10, 178-188	52
22	Intermittent Fasting: A User-Friendly Method for Type 2 Diabetes Mellitus.. 2021 , 13, e19348	
21	Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis. 2021 , 42, 101213	5
20	Pharmacology, Biodiversity and. 2021 ,	
19	Association Between the EAT-Lancet Diet Pattern and Risk of Type 2 Diabetes: A Prospective Cohort Study.. 2021 , 8, 784018	2
18	Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.. 2022 , 13, 838410	2
17	Investigating Potential GLP-1 Receptor Agonists in Cyclopeptides from Pseudostellaria heterophylla, Linum usitatissimum, and Drymaria diandra, and Peptides Derived from Heterophyllin B for the Treatment of Type 2 Diabetes: An In Silico Study. 2022 , 12, 549	1
16	Association of Time in Range with Endothelial Injury in Patients with Type 2 Diabetes Treated with Exenatide.	

15	WITHDRAWN: American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan 2022 Update. 2022 ,	8
14	Exenatide increases CTRP3 gene expression in adipose cells by inhibiting adipogenesis and induces apoptosis. 2022 , 85, 105479	0
13	Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. 2022 , 21,	8
12	Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: Systematic review and meta-analysis. 2022 , 100456	0
11	Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus. 2022 , 2022, 1-6	0
10	Comparison of Glucose Lowering Efficacy of Human GLP-1 Agonist in Taiwan Type 2 Diabetes Patients after Switching from DPP-4 Inhibitor Use or Non-Use. 2022 , 12, 1915	0
9	Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations. 2022 , 2022, 1-9	0
8	Weight-centric treatment of type 2 diabetes mellitus. 2022 , 4, 100045	0
7	Disparities in the Use of SGLT2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Adults With CKD in the United States. 2022 , 100590	0
6	GLP-1R Signaling and Functional Molecules in Incretin Therapy. 2023 , 28, 751	0
5	Adverse Events Related to Tirzepatide. 2023 , 7,	0
4	Clinical Evidence of Low-Carbohydrate Diets against Obesity and Diabetes Mellitus. 2023 , 13, 240	0
3	Variation in responses to incretin therapy: Modifiable and non-modifiable factors. 10,	0
2	A novel peptide isolated from <i>Aphonopelma chalcodes tarantula</i> venom with benefits on pancreatic islet function and appetite control. 2023 , 212, 115544	0
1	Diabetic Kidney Disease in Post-Transplant Diabetes Mellitus: Causes, Treatment and Outcomes. 2023 , 11, 470	0